Document:

ex101.htm

SHARE PURCHASE AGREEMENT

This SHARE PURCHASE AGREEMENT (“Agreement”) is entered into and made effective as of the 25th day of June, 2014 by and between First Liberty Power Corp., a Nevada Corporation ("First Liberty" or “Buyer”), Group8 Minerals, a Nevada Corporation ("Group8”), and Group8 Mining Innovations, a Nevada Corporation (“G8MI” or “Seller”), a shareholder of Group8 (singularly, a “Party” and collectively, the “Parties”).

WHEREAS, Seller is the one nineteen percent (19%) shareholder of Group8, and upon the terms and conditions set forth below, Seller desires to transfer 19% of the total issued and outstanding shares of Group8 owned by Seller to Buyer; and

WHEREAS, Group8 holds a fifty percent (50%) interest in and to certain Nevada limited liability companies, as detailed in Schedule A attached hereto (the “Projects”).

NOW, THEREFORE, in consideration of the mutual covenants, agreements, representations and warranties contained in this Agreement, the Parties hereto agree as follows:

1.    SALE AND PURCHASE OF SHARES.

1.1           PURCHASE.  Subject to the terms and conditions herein set forth, First Liberty hereby agrees to purchase and Seller hereby agrees to sell its entire interest, representing nineteen percent (19%), or 1,740,400 shares, of the issued and outstanding shares of common stock of Group8 (the “Group8 Shares”) to First Liberty.

1.2 CONSIDERATION.  The Share Consideration to be issued to G8MI upon the Closing of the acquisition of the Group8 Shares shall be a total of 5,000,000 shares of First Liberty Power Corp “Series A Preferred Stock”.

2.  REPRESENTATIONS AND WARRANTIES

2.1           REPRESENTATIONS AND WARRANTIES OF Group8 and Seller. Group8 and Seller each represent and warrant as follows:

	
a)  

	
CORPORATE ORGANIZATION AND GOOD STANDING.  Group8 and Seller are each duly organized, validly existing, and in good standing under the laws of the State of Nevada and are qualified to do business as a foreign corporation in each jurisdiction, if any, in which their respective properties or businesses require such qualification.

	
b)  

	
CORPORATE AUTHORITY.  Group8 and Seller each have all requisite corporate power and authority to own, operate and lease their respective properties, to carry on their respective businesses as it is now being conducted and to execute, deliver, perform and conclude the transactions contemplated by this Agreement and all other agreements and instruments related to this Agreement.

	
c)  

	
AUTHORIZATION.  Execution of this Agreement has been duly authorized and approved by each of Group8 and the Seller. Further Group8 has obtained all requisite shareholder approval and authority to enter into this Agreement and deliver, perform and conclude the transactions contemplated by this Agreement and all other agreements and instruments related to this Agreement.

  

Page 1 of 16

  

	
d)  

	
CAPITALIZATION.

	
i)  

	
The authorized capital stock of Group8 consists of 50,000,000 shares of Group8 Common Stock $0.001 par value. At June 25, 2014, (i) 9,160,000 shares of Group8 Common Stock were issued and outstanding, all of which are duly authorized, validly issued, fully paid and non-assessable and none of which were issued in violation of any preemptive rights; (ii) no shares of Group8 were reserved for issuance upon the exercise of outstanding options, warrants or other rights to purchase shares; and (iii) no shares of Group8 stock were held in the treasury of Group8.  Except as set forth above, as of the date hereof, no shares or other voting securities of Group8 are issued, reserved for issuance or outstanding and no shares or other voting securities of Group8 shall be issued or become outstanding after the date hereof.  There are no bonds, debentures, notes or other indebtedness or securities of Group8 that have the right to vote (or that are convertible into, or exchangeable for, securities having the right to vote) on any matters on which stockholders of Group8 may vote.

	
ii)  

	
Group8 has no contract or other obligation to repurchase, redeem or otherwise acquire any shares of Group8 stock, or make any investment (in the form of a loan, capital contribution or otherwise) in any other Person.  There are no outstanding subscriptions, options, warrants, puts, calls, rights, exchangeable or convertible securities or other commitments or agreements of any character relating to the issued or unissued shares or other securities of Group8.  None of the outstanding equity securities or other securities of Group8 was issued in violation of the Securities Act of 1933 or any other legal requirement.

	
e)  

	
LITIGATION.  To the knowledge of Group8 and Seller, there are no pending, threatened, or existing litigation, bankruptcy, criminal, civil, or regulatory proceeding or investigation, threatened or contemplated against Group8 or Seller.

	
f)  

	
FINANCIAL STATEMENTS.

	
i)  

	
Seller has furnished or made available to Buyer, or will make available to Buyer prior to the Closing Date, true and complete copies of the financial statements (and the related notes thereto) of Group8 from inception to July 31, 2013 (the “Seller Financial Statements”).

	
ii)  

	
The Group8 Financial Statements were prepared in accordance with GAAP or the equivalent applied on a basis consistent throughout the periods indicated (except as otherwise stated in such financial statements, including the related notes).

  

Page 2 of 16

  

	
g)  

	
ABSENCE OF CERTAIN CHANGES OR EVENTS.  Since inception and to the date of this Agreement, (i) Group8 has, in all material respects, conducted its business in the ordinary course consistent with past practice; (ii) there has not occurred any change, event or condition that is or would reasonably be expected to result in a material adverse effect, as defined in Section 3.2(a) (“Material Adverse Effect”); and (iii) Group8 has not taken and will not take any of the actions that Group8 has agreed not to take from the date hereof through the Closing Date.

	
h)  

	
UNDISCLOSED LIABILITIES.  Group8 has no material obligations or liabilities of any nature (whether accrued, matured or unmatured, fixed or contingent or otherwise) other than: (i) those set forth Seller Financial Statements; (ii) those incurred in the ordinary course of business consistent with past practice since the end of the most recent fiscal year; and (iii) those incurred in connection with the execution of this Agreement.

	
i)  

	
LEGAL PROCEEDINGS.  Neither Group8 nor Seller is not a party to any, and there is no pending or, to the knowledge of Seller or Group8, threatened, legal, administrative, arbitral or other proceeding, claim, action or governmental or regulatory investigation of any nature against Seller or Group8, or any of their respective officers or directors which, if decided adversely to Seller or Group8, would, individually or in the aggregate, be material to Seller or Group8.  There is no injunction, order, judgment or decree imposed upon Seller or Group8, or any of its officers or directors, or the assets of Seller or Group8.

	
j)  

	
TAXES AND TAX RETURNS.

	
i)  

	
Group8 does have a requirement to file tax returns as at the date of this Agreement, however, it shall provide to Buyer such information required to file all existing and future tax returns, such filings shall become the responsibility of the Buyer.

	
ii)  

	
No national, state, local or foreign audits, examinations, investigations, or other formal proceedings are pending or, to Group8’s knowledge, threatened with regard to any taxes of Group8.  No issue has arisen in any examination of the Group8 by any tax authority that if raised with respect to any other period not so examined would result in a material deficiency for any other period not so examined, if upheld.

	
iii)  

	
There are no disputes pending with respect to, or claims or assessments asserted in writing for, any material amount of taxes upon Buyer, nor has Group8 given or been requested in writing to give any currently effective waiver extending the statutory period of limitation applicable to any tax return for any period.

	
k)  

	
COMPLIANCE WITH APPLICABLE LAW AND REGULATORY MATTERS.

	
i)  

	
Group8 has complied with all applicable laws and regulations, and are not in violation of, and have not received any written notices of violation with respect to, any laws and regulations in connection with the conduct of their respective businesses or the ownership or operation of their respective businesses, assets and properties, except for such noncompliance and violations as would not, individually or in the aggregate, be material.

  

Page 3 of 16

  

	
ii)  

	
Group8 has all licenses, permits, certificates, franchises and other authorizations (collectively, the “Authorizations”) necessary for the ownership or use of its assets and properties and the conduct of its business, as currently conducted, and have complied with, and are not in violation of, any Authorization.  All such Authorizations are in full force and effect and there are no proceedings pending or, to the knowledge of Group8, threatened that seek the revocation, cancellation, suspension or adverse modification thereof.

	
iii)  

	
There are no governmental orders applicable to Group8 which have had a Material Adverse Effect on Group8.

	
l)  

	
MATERIAL CONTRACTS.  There are no material contracts of Group8 currently in existence except as disclosed in a Schedule hereto.

	
m)  

	
ASSETS.  Group8 owns, leases or has the right to use all the properties and assets necessary or currently used for the conduct of its businesses free and clear of all liens of any kind or character.  All items of equipment and other tangible assets owned by or leased to Group8 and which are material to the operations and business of Group8 are in good condition and repair (ordinary wear and tear excepted).  In the case of leased equipment and other tangible assets, Group8 holds valid leasehold interests in such leased equipment and other tangible assets, free and clear of all liens of any kind or character.

	
n)  

	
ENVIRONMENTAL LIABILITY.  Group8 is in compliance with all applicable environmental laws.  To the knowledge of Group8, there are no liabilities of Group8 of any kind, whether accrued, contingent, absolute, determined, determinable or otherwise arising under or relating to any environmental law and, to the knowledge of Group8, there are no facts, conditions, situations or set of circumstances that could reasonably be expected to result in or be the basis for any such liability.

	
o)  

	
INTELLECTUAL PROPERTY. Group8 has no intellectual property.

	
p)  

	
INTERESTS OF OFFICERS AND DIRECTORS.  Except as disclosed herein, none of the officers or directors of Group8 has any interest in any property, real or personal, tangible or intangible, including intellectual property, used in or developed by the business of Group8, or in any supplier, distributor or customer of Group8, or any other relationship, contract, agreement, arrangement or understanding with Group8, except for the normal ownership interests of a shareholder and employee rights.

	
q)  

	
BROKER’S FEES.  Group8 has not employed any broker or finder or incurred any liability for any broker’s fees, commissions or finder’s fees in connection with the transactions contemplated by this Agreement.

  

Page 4 of 16

  

	
r)  

	
CERTAIN BUSINESS PRACTICES.  No director, officer, agent or employee of Group8 has (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity on behalf of, or purportedly on behalf of, or for the business of Group8, or (ii) made any unlawful payments to officials or employees of governmental entities or to directors, officers or employees of foreign or domestic business enterprises.

2.2           REPRESENTATIONS AND WARRANTIES OF BUYER. The Buyer represents and warrants as follows:

	
  

	
a)

	
CORPORATE ORGANIZATION AND GOOD STANDING.  Buyer is a corporation duly organized, validly existing, and in good standing under the laws of the State of Nevada, and is qualified to do business as a foreign corporation in each jurisdiction, if any, in which its property or business requires such qualification.

	
  

	
b)

	
CORPORATE AUTHORITY.  Buyer has all requisite corporate power and authority to execute, deliver, perform and conclude the transactions contemplated by this Agreement and all other agreements and instruments related to this Agreement.

	
  

	
c)

	
NO VIOLATION.  Consummation of the acquisition contemplated herein will not constitute or result in a breach or default under any provision of any charter, bylaw, indenture, mortgage, lease, or agreement, or any order, judgment, decree, law, or regulation by which Buyer is bound.

	
  

	
d)

	
REPORTING STATUS. Buyer is a fully reporting public company under Section 15(d) of the Securities and Exchange Act of 1934, as amended, and is current on its filing obligations under Section 15.  Buyer has filed all required periodic reports with the Securities and Exchange Commission (the "Commission") on Forms 10-Q and 10-K through the period ended April 30, 2012, and all required Form 8-K reports, all such reports are true and correct in all material respects and contain no misrepresentation of a material fact or omission of a material fact.  The common shares of Buyer are quoted on the OTC Markets under the symbol "FLPC".  Buyer has not received and there are no outstanding Commission Staff comment letters, stop orders or other regulatory actions, and no letters, comments, investigations or other actions pending or threatened by the Commission or by the Financial Industry Regulatory Authority (FINRA) against or relating to Buyer and there are no outstanding fees, fines or other amounts due to FINRA, the SEC, PCAOB or any other regulatory agency.  Buyer acknowledges that it currently has a cease trade order outstanding against Buyer in the Province of British Columbia, Canada.

 

	
  

	
e)

	
CAPITALIZATION

 

	
(i)  

	
On the date of this Agreement, 1,080,000,000 shares of $0.001 par value common stock are authorized and 671,556,096 shares of common stock of Buyer are issued and outstanding; all of the shares of common stock issued are duly authorized, validly issued, fully paid and non-assessable and none were issued in violation of any preemptive rights;

  

Page 5 of 16

  

	
(ii)  

	
On the date of this Agreement, 10,000,000 shares of $0.001 par value each, which shares are designated as “Preferred Stock”, and which may be issued in one or more classes or series, with such rights, preferences, privileges and restrictions as will be fixed at the discretion of the Board of Directors.  Of the 10,000,000 shares of Preferred Stock, 5,000,000 shares have been designated by the Board of Directors as “Series A Preferred Stock”, having such rights, preferences, privileges and restrictions as identified in the Buyer’s public filings.  No Series A Preferred Stock has been issued, and these 5,000,000 shares are to form consideration under this Agreement;

	
(iii)  

	
Certain shares of Buyer are reserved for issuance upon the exercise of outstanding options, warrants or other rights to purchase shares, as required under certain convertible debentures held by the Company and other agreements as entered into or held by the Company as of the date of this Agreement, and have been duly disclosed in full in the Company’s regulatory filings;

	
(iv)  

	
Except as set forth above, as of the date hereof, no shares or other voting securities of Buyer are issued, reserved for issuance or outstanding and no shares or other voting securities of Buyer shall be issued or become outstanding after the date hereof, save for those Shares to be issued pursuant to this Agreement.  There are no bonds, debentures, notes or other indebtedness or securities of Buyer that have the right to vote (or that are convertible into, or exchangeable for, securities having the right to vote) on any matters on which stockholders of Buyer may vote.  All shares of Buyer subject to issuance as described above shall, upon issuance on the terms and conditions specified in the instruments pursuant to which they are issuable, be duly authorized, validly issued, fully paid, non-assessable and free of preemptive rights.

	
(v)  

	
Buyer has no contract or other obligation to repurchase, redeem or otherwise acquire any shares of Buyer stock, or make any investment (in the form of a loan, capital contribution or otherwise) in any other Person.  There are no outstanding subscriptions, options, warrants, puts, calls, rights, exchangeable or convertible securities or other commitments or agreements of any character relating to the issued or unissued shares or other securities of Buyer.  None of the outstanding equity securities or other securities of Buyer was issued in violation of the Securities Act of 1933 or any other legal requirement.

	
f)  

	
AUTHORITY; NO VIOLATION.

	
  

	
(i)

	
Buyer has full corporate power and authority to execute and deliver this Agreement and to comply with the terms hereof and consummate the transactions contemplated hereby.  This Agreement has been duly and validly executed and delivered by Buyer.  Assuming due authorization, execution and delivery by the other Parties, this Agreement constitutes the valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, except as such enforcement may be limited by (i) the effect of bankruptcy, insolvency, reorganization, receivership, conservatorship, arrangement, moratorium or other similar laws affecting or relating to the rights of creditors generally, or (ii) the rules governing the availability of specific performance, injunctive relief or other equitable remedies and general principles of equity, regardless of whether considered in a proceeding in equity or at law, or (iii) the specific terms and conditions of this Agreement.

  

Page 6 of 16

  

	
  

	
(ii)

	
Neither the execution and delivery of this Agreement by Buyer nor the consummation by Buyer of the transactions contemplated hereby, nor compliance by Buyer with any of the terms or provisions hereof, will (A) violate any provision of the Certificate of Registration or Constitution or the certificates of registration or constitution, or other charter or organizational documents, of Buyer or (B) violate any statute, code, ordinance, rule, regulation, judgment, order, writ, decree or injunction applicable to Buyer or any of its properties or assets, the violation of which would have a material adverse effect, or (C) violate, conflict with, result in a breach of any provision of or the loss of any material benefit under, constitute a default (or an event which, with notice or lapse of time, or both, would constitute a default) under, result in the termination of any or all rights or benefits or a right of termination or cancellation under, accelerate the performance required by or rights or obligations under, increase any rate of interest payable or result in the creation of any lien upon any of the respective properties or assets of Buyer under, any authorization or of the terms, conditions or provisions of any note, bond, mortgage, indenture, deed of trust, license, lease, agreement, contract, or other instrument or obligation to which is a party, or by which its properties, assets or business activities may be bound or affected.

	
g)  

	
FINANCIAL STATEMENTS.

	
  

	
(i)

	
Buyer has furnished or made available to Seller, or will make available to Seller prior to the Closing Date, true and complete copies of the audited financial statements of Buyer for the past two fiscal years (the “Buyer Financial Statements”), and Buyer shall furnish or make available to Seller true and complete copies of Buyer's Financial Statements for all monthly periods ending after its most recent fiscal year up to and including the Closing Date.

	
  

	
(ii)

	
The Buyer Financial Statements were prepared in accordance with GAAP or the equivalent applied on a basis consistent throughout the periods indicated (except as otherwise stated in such financial statements, including the related notes, and except that, in the case of unaudited statements for the subsequent quarterly periods referenced above, such unaudited statements fairly present in all material respects the consolidated financial condition and the results of operations of Buyer as at the respective dates thereof and for the periods indicated therein (subject, in the case of unaudited statements, to year-end audit adjustments).

	
h)  

	
ABSENCE OF CERTAIN CHANGES OR EVENTS.  Since the end of its most recent fiscal year and to the date of this Agreement, (i) Buyer has, in all material respects, conducted its business in the ordinary course consistent with past practice; (ii) there has not occurred any change, event or condition that is or would reasonably be expected to result in a material adverse effect; and (iii)  Buyer has not taken and will not take any of the actions that Buyer has agreed not to take from the date hereof through the Closing.

  

Page 7 of 16

  

	
i)  

	
UNDISCLOSED LIABILITIES.  Buyer has no material obligations or liabilities of any nature (whether accrued, matured or unmatured, fixed or contingent or otherwise) other than (i) those set forth or adequately provided for in the balance sheet (and the related notes thereto) of Buyer as of the end of the most recent fiscal year  included in the Buyer Financial Statements, (ii) those incurred in the ordinary course of business consistent with past practice since the end of the most recent fiscal year  and (iii) those incurred in connection with the execution of this Agreement.

	
j)  

	
LEGAL PROCEEDINGS.  Buyer is not a party to any, and there is no pending or, to the knowledge of Buyer, threatened, legal, administrative, arbitral or other proceeding, claim, action or governmental or regulatory investigation of any nature against Buyer, or any of its officers or directors which, if decided adversely to Buyer, would, individually or in the aggregate, be material to Buyer.  There is no injunction, order, judgment or decree imposed upon Buyer, or any of its officers or directors, or the assets of Buyer.

	
k)  

	
TAXES AND TAX RETURNS.

	
(i)  

	
Buyer has filed or caused to be filed all  federal, state, foreign and local tax returns required to be filed with any tax authority; (ii) all such tax returns are true, accurate, and complete in all material respects; (iii) Buyer has paid or caused to be paid all taxes that are due and payable by any of such companies, other than taxes which are being contested in good faith and are adequately reserved against or provided for (in accordance with  GAAP) in the Buyer Financial Statements, and (iv) Buyer does not have any material liability for taxes for any current or prior tax periods in excess of the amount reserved or provided for in the Buyer Financial Statements (but excluding, for this Clause (iv) only, any liability reflected thereon for deferred taxes to reflect timing differences between tax and financial accounting methods).

	
(ii)  

	
No national, state, local or foreign audits, examinations, investigations, or other formal proceedings are pending or, to Buyer’s knowledge, threatened with regard to any taxes or tax returns of Buyer.  No issue has arisen in any examination of the Buyer by any tax authority that if raised with respect to any other period not so examined would result in a material deficiency for any other period not so examined, if upheld.  Any adjustment of income taxes of Buyer made in any examination that is required to be reported to the appropriate national, state, local or foreign tax authorities has been so reported.

	
(iii)  

	
There are no disputes pending with respect to, or claims or assessments asserted in writing for, any material amount of taxes upon Buyer, nor has Buyer given or been requested in writing to give any currently effective waiver extending the statutory period of limitation applicable to any tax return for any period.

  

Page 8 of 16

  

	
l)  

	
COMPLIANCE WITH APPLICABLE LAW AND REGULATORY MATTERS.

	
i)  

	
Buyer has complied with all applicable laws and regulations, and are not in violation of, and have not received any written notices of violation with respect to, any laws and regulations in connection with the conduct of their respective businesses or the ownership or operation of their respective businesses, assets and properties, except for such noncompliance and violations as would not, individually or in the aggregate, be material.

	
ii)  

	
Buyer has all licenses, permits, certificates, franchises and other authorizations (collectively, the “Authorizations”) necessary for the ownership or use of its assets and properties and the conduct of its business, as currently conducted, and have complied with, and are not in violation of, any Authorization, except where such noncompliance or violation would not, individually or in the aggregate, be material.  Except as would not be material to Buyer, all such Authorizations are in full force and effect and there are no proceedings pending or, to the knowledge of Buyer, threatened that seek the revocation, cancellation, suspension or adverse modification thereof.

	
m)  

	
GOVERNMENT ORDERS. There are no governmental orders applicable to Buyer which have had a Material Adverse Effect on Buyer.

	
n)  

	
MATERIAL CONTRACTS.  There are no material contracts of Buyer currently in existence not disclosed with the Buyer’s filings with the SEC.

	
o)  

	
ASSETS.  Buyer owns, leases or has the right to use all the properties and assets necessary or currently used for the conduct of its businesses free and clear of all liens of any kind or character.  All items of equipment and other tangible assets owned by or leased to Buyer and which are material to the operations and business of Buyer are in good condition and repair (ordinary wear and tear excepted).  In the case of leased equipment and other tangible assets, Buyer holds valid leasehold interests in such leased equipment and other tangible assets, free and clear of all liens of any kind or character.  At Closing all assets and liabilities of Buyer shall be disposed of and Buyer shall have no assets or liabilities.

	
p)  

	
ENVIRONMENTAL LIABILITY.  Buyer is in compliance with all applicable environmental laws.  To the knowledge of Buyer, there are no liabilities of Buyer of any kind, whether accrued, contingent, absolute, determined, determinable or otherwise arising under or relating to any environmental law and, to the knowledge of Buyer, there are no facts, conditions, situations or set of circumstances that could reasonably be expected to result in or be the basis for any such liability.

	
q)  

	
INSURANCE.  Buyer has no insurance coverage with respect to its business.

  

Page 9 of 16

  

	
r)  

	
INTELLECTUAL PROPERTY. Buyer has no intellectual property.

	
s)  

	
INTERESTS OF OFFICERS AND DIRECTORS.  Except AS DISCLOSED HEREIN, OR IN PRIOR REGULATORY FILINGS WITH THE SEC, None of the officers or directors of Buyer has any interest in any property, real or personal, tangible or intangible, including intellectual property, used in or developed by the business of Buyer, or in any supplier, distributor or customer of Buyer, or any other relationship, contract, agreement, arrangement or understanding with Buyer, except for the normal ownership interests of a shareholder and employee rights.

	
t)  

	
BROKER’S FEES.  Buyer has not employed any broker or finder or incurred any liability for any broker’s fees, commissions or finder’s fees in connection with the transactions contemplated by this Agreement.

	
u)  

	
CERTAIN BUSINESS PRACTICES.  No director, officer, agent or employee of Buyer has (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity on behalf of, or purportedly on behalf of, or for the business of Buyer, or (ii) made any unlawful payments to officials or employees of governmental entities or to directors, officers or employees of foreign or domestic business enterprises.

3.  CONDITIONS PRECEDENT

3.1           Conditions to Each Party’s Obligations. The respective obligations of each Party hereunder shall be subject to the satisfaction prior to or at the Closing Date of the following conditions:

	
  

	
a)

	
No Restraints. No statute, rule, regulation, order, decree, or injunction shall have been enacted, entered, promulgated, or enforced by any court or governmental entity of competent jurisdiction which enjoins or prohibits the consummation of this Agreement and shall be in effect.

	
  

	
b)

	
Legal Action. There shall not be pending or threatened in writing any action, proceeding, or other application before any court or governmental entity challenging or seeking to restrain or prohibit the consummation of the transactions contemplated by this Agreement, or seeking to obtain any material damages.

  

Page 10 of 16

  

3.2           Conditions to Seller’s Obligations. The obligations of Seller shall be subject to the satisfaction prior to or at the Closing Date of the following conditions unless waived by Seller:

	
  

	
a)

	
Representatives and Warranties of Buyer. The representations and warranties of Buyer set forth in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date, except: (i) as otherwise contemplated by this Agreement; or (ii) in respects that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement. “Material Adverse Effect” for purposes of this Agreement shall mean any change or effect that, individually or when taken together with all other such changes or effects which have occurred prior to the date of determination of the occurrence of the Material Adverse Effect, is or is reasonably likely to be materially adverse to the business, assets, financial condition, or results of operation of the entity.

	
  

	
b)

	
Performance of Obligations of Buyer. Buyer shall have performed all agreements and covenants required to be performed by it under this Agreement prior to the Closing, except for breaches that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement.

3.3           Conditions to Buyer’s Obligations. The obligations of Buyer shall be subject to the satisfaction prior to or at the Closing Date of the following conditions unless waived by Buyer:

	 	
a)  

	
Representatives and Warranties of Group8 and Seller. The representations and warranties of Group8 and Seller set forth in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date, except: (i) as otherwise contemplated by this Agreement, or (ii) in respects that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement.

	
  

	
b)

	
Performance of Seller and Group8. Seller and Group8 shall have performed all agreements and covenants required to be performed by them under this Agreement prior to Closing, except for breaches that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement.

4. CLOSING DATE AND DELIVERY OF DOCUMENTS

4.1           Time and Place. The Closing of the transaction contemplated by this Agreement shall take place at the offices of Group8, unless otherwise agreed by the Parties, immediately upon the full execution of this Agreement (the “Closing Date”), and the satisfaction of all conditions, specifically the delivery of all required documents, or at such other time and place as the Parties mutually agree.  All proceedings to be taken and all documents to be executed at the Closing shall be deemed to have been taken, delivered and executed simultaneously, and no proceeding shall be deemed taken nor documents deemed executed or delivered until all have been taken, delivered and executed.  The date of Closing may be accelerated or extended by agreement of the parties.

Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission required by this Agreement or any signature required thereon may be used in lieu of an original writing or transmission or signature for any and all purposes for which the original could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission or original signature.

  

Page 11 of 16

  

4.2           Deliveries by Seller and Group8. At the Closing Date, Seller shall make the following deliveries to Buyer:

	
  

	
a)

	
Copies of resolutions of the Board of Directors and Shareholders of Seller and Group8 authorizing the execution and performance of this Agreement.

	
  

	
b)

	
Stock certificates of Group8 representing the Group8 Shares, fully endorsed for transfer to Buyer.

	
4.3  

	
Deliveries by Buyer. At Closing, Buyer shall make the following deliveries to Seller:

 

	
  

	
a)

	

Stock certificate(s), bearing any applicable restrictive legends, representing the First Liberty “Series A Preferred Shares” issued in the name of Seller or its designee;

	
  

	
b)

	
Resolutions of the Board of Directors of Buyer authorizing the execution and performance of this Agreement.

 

5.  INDEMNIFICATION AND ARBITRATION

5.1           Indemnification. The Seller and Group8, on the one hand, and the Buyer, on the other hand, (each party, “Indemnifying Party”) shall agree to indemnify, and hold harmless the other party (“Indemnified Party”) from any and all claims, demands, liabilities, damages, losses, costs and expenses that the other party shall incur or suffer, including attorneys’ fees and costs, that arise, result from or relate to any breach of, or failure by Indemnifying Party to perform any of their respective representations, warranties, covenants, or agreements in this Agreement or in any exhibit, addendum, or any other instrument furnished by the Indemnifying Party under this Agreement.

5.2           Arbitration and Governing Law. The parties hereby agree that any and all claims (except only for requests for injunctive or other equitable relief) whether existing now, in the past or in the future as to which the parties or any affiliates may be adverse parties, and whether arising out of this Agreement or from any other cause, will be resolved by arbitration before the American Arbitration Association within the State of Nevada.

	
  

	
a)

	
The parties hereby irrevocably consent to the jurisdiction of the American Arbitration Association and the status of the arbitration (and any requests for injunctive or other equitable relief) within the State of Nevada.  Any award in arbitration may be entered in any domestic or foreign court having jurisdiction over the enforcement of such awards.

	
  

	
b)

	
The law applicable to the arbitration and this Agreement shall be that of the State of Nevada, determined without regard to its provisions which would otherwise apply to a question of conflict of laws.

	
  

	
c)

	
The arbitrator may, in its discretion, allow the parties to make reasonable disclosure and discovery in regard to any matters which are the subject of the arbitration and to compel compliance with such disclosure and discovery order.  The arbitrator may order the parties to comply with all or any of the disclosure and discovery provisions of the Federal Rules of Civil Procedure, as they then exist, as may be modified by the arbitrator consistent with the desire to simplify the conduct and minimize the expense of the arbitration.

  

Page 12 of 16

  

	
  

	
d)

	
Regardless of any practices of arbitration to the contrary, the arbitrator will apply the rules of contract and other law of the jurisdiction whose law applies to the arbitration so that the decision of the arbitrator will be, as much as possible, the same as if the dispute had been determined by a court of competent jurisdiction.

	
  

	
e)

	
Any award or decision by the American Arbitration Association shall be final, binding and non-appealable except as to errors of law or the failure of the arbitrator to adhere to the arbitration provisions contained in this agreement.  Each party to the arbitration shall pay its own costs and counsel fees except as specifically provided otherwise in this agreement.

	
  

	
f)

	
In any adverse action, the parties shall restrict themselves to claims for compensatory damages and\or securities issued or to be issued and no claims shall be made by any party or affiliate for lost profits, punitive or multiple damages.

	
  

	
g)

	
The parties covenant that under no conditions will any party or any affiliate file any action against the other (except only requests for injunctive or other equitable relief) in any forum other than before the American Arbitration Association, and the parties agree that any such action, if filed, shall be dismissed upon application and shall be referred for arbitration hereunder with costs and attorney's fees to the prevailing party.

	
  

	
h)

	
It is the intention of the parties and their affiliates that all disputes of any nature between them, whenever arising, whether in regard to this agreement or any other matter, from whatever cause, based on whatever law, rule or regulation, whether statutory or common law, and however characterized, be decided by arbitration as provided herein and that no party or affiliate be required to litigate in any other forum any disputes or other matters except for requests for injunctive or equitable relief. This agreement shall be interpreted in conformance with this stated intent of the parties and their affiliates.

The provisions for arbitration contained herein shall survive the termination of this agreement for any reason.

6.  GENERAL PROVISIONS.

6.1           FURTHER ASSURANCES.  From time to time, each party will execute such additional instruments and take such actions as may be reasonably required to carry out the intent and purposes of this Agreement.

6.2           WAIVER.  Any failure on the part of either party hereto to comply with any of its obligations, agreements, or conditions hereunder may be waived in writing by the party to whom such compliance is owed.

6.3           BROKERS.  Each party agrees to indemnify and hold harmless the other party against any fee, loss, or expense arising out of claims by brokers or finders employed or alleged to have been employed by the indemnifying party.

  

Page 13 of 16

  

6.4           NOTICES.  All notices and other communications hereunder shall be in writing and shall be given by personal delivery, overnight delivery, mailed by registered or certified mail, postage prepaid, with return receipt requested, as follows:

If to Seller and Group8, to:

Attn:       Board of Directors

13785 Research Blvd Ste 125

Austin, TX  78750

If to Buyer, to:

Attn:        Board of Directors

7251 West Lake Blvd, Suite 300

Las Vegas, NV  89128

The persons and addresses set forth above may be changed from time to time by a notice sent as aforesaid.  If notice is given by personal delivery or overnight delivery in accordance with the provisions of this Section, such notice shall be conclusively deemed given at the time of such delivery provided a receipt is obtained from the recipient.  If notice is given by mail, such notice shall be deemed given upon receipt and delivery or refusal.

6.5           ASSIGNMENT.  This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their successors and assigns; provided, however, that any assignment by either party of its rights under this Agreement without the written consent of the other party shall be void.

6.6           COUNTERPARTS.  This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Signatures sent by facsimile transmission shall be deemed to be evidence of the original execution thereof.

6.7           REVIEW OF AGREEMENT.  Each party acknowledges that it has had time to review this agreement and, as desired, consult with counsel.  In the interpretation of this Agreement, no adverse presumption shall be made against any party on the basis that it has prepared, or participated in the preparation of, this Agreement.

6.8           SCHEDULES.  All schedules attached hereto, if any, shall be acknowledged by each party by signature or initials thereon.

  

Page 14 of 16

  

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement on the date first written above

 

FIRST LIBERTY POWER CORP.

By:              

Robert Reynolds

GROUP8 MINERALS

By:              

Dimitrios S. Trikeriotis

GROUP8 MINING INNOVATIONS

By:              

Dimitrios S. Trikeriotis

  

Page 15 of 16

  

Schedule A

Group8 holds a fifty percent (50%) interest in and to certain Nevada limited liability companies, as follows:

	
·  

	
Stockpile Reserves, LLC, as to the applicable Operating Agreement and Membership Subscription Agreement, which company holds the rights to certain unpatented mining claims in Pershing county, Nevada, known as Fencemaker.

	
·  

	
Central Nevada Processing Co. LLC, as to the applicable Operating Agreement and Membership Subscription Agreement, which company occupies certain land in Lovelock, Nevada, with applicable pending permitting for the operation of a milling and refining facility.

	
·  

	
SG8 Exploration, LLC, as to the applicable Operating Agreement and Membership Subscription Agreement, which company holds certain unpatented mining claims in Pershing County, Nevada, and which claim details have been provided to Buyer confidentially, to allow Buyer certain time to perform additional staking around such claims if so desired.

  

Page 16 of 16EX-10.1

 Exhibit 10.1 

Execution Version 
 CONFIDENTIAL TREATMENT
REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
 LICENSE AGREEMENT

 This License Agreement (this “Agreement”), effective as of September 29, 2006 (the “Effective
Date”), is entered into by and between XOMA Ireland Limited, a company with limited liability organized under the laws of the Republic of Ireland having offices at Shannon Airport House, Shannon, County Clare, Ireland (with its Affiliates,
“XOMA”), and Affimed Therapeutics AG, a company organized under the laws of the Federal Republic of Germany, with offices at Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (with its Affiliates,
“AFFIMED”). 
 BACKGROUND 

A. XOMA is the owner or exclusive licensee of certain patent rights and know-how relating to bacterial cell expression, and AFFIMED wishes to
acquire non-exclusive licenses under such patent rights and know-how; and 
 B. XOMA is willing to grant AFFIMED non-exclusive licenses, on
the terms and conditions set forth below, in order to permit AFFIMED to engage in certain research, development and commercial activities; and 

C. XOMA wishes to engage AFFIMED to construct libraries of immunoglobulin genes under instructions from XOMA; and 

D. AFFIMED is the owner or exclusive licensee of certain patent rights and know-how relating to bacterial construction of immunoglobulin
libraries, and XOMA wishes to acquire non-exclusive licenses under such patent rights and the AFFIMED Technology (as defined below); and 

E. AFFIMED and XOMA wish to enter into a collaborative arrangement pursuant to which XOMA will scale up the manufacture of and make a Tandab
(as defined below) for AFFIMED. 
 NOW, THEREFORE, in consideration of the promises and the mutual covenants hereinafter recited, the
parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 In this Agreement,
the following terms shall have the meanings set forth in this Article. 
 1.1. “Affiliate” means any corporation or other
entity which is directly or indirectly controlling, controlled by or under common control with a party hereto. For purposes of this Agreement, “control” (including, with correlative meanings, the terms “controlled”
and “controlling”) means the possession, directly or indirectly, of the power 

 
to direct or cause the direction of the management or policies of the subject corporation or other entity, whether through the ownership of voting securities, by agreement or otherwise. 

1.2. “AFFIMED Collaborator” means a Third Party (a) either (i) from whom AFFIMED in-licenses a target or, solely as
provided for under Section 2.6, the variable domains of a ScFv subsequently incorporated into a Tandab or Flexibody for development and/or commercialization or (ii) with whom AFFIMED shares the economic risk of development or
commercialization of a target or Immunoglobulin being developed or commercialized on behalf of AFFIMED and (b) who, pursuant to the terms of a bona fide written collaboration agreement, in the AFFIMED Field, engages in Research with AFFIMED, is
the intended recipient of a Licensed Immunoglobulin or Licensed Immunoglobulin Information transferred from AFFIMED or is the party in a collaboration relating to one or more Tandabs who will develop, distribute or sell such Tandab(s) subject to
Article 3 of this Agreement; provided, however, that such person or entity shall not be deemed to be an AFFIMED Collaborator unless and until the requirements of Section 2.4 are complied with. No person or entity shall be permitted or
deemed to be an AFFIMED Collaborator if such person or entity, either as of the date of its written agreement with AFFIMED or thereafter, is or was (a) infringing any XOMA Patent Rights; (b) engaged in the research, development or
commercialization of an Immunoglobulin discovered, isolated or characterized by the use of Antibody Phage Display or under conditions which infringe any of the XOMA Patent Rights and/or (c) engaged in a Commercial Antibody Phage Display
Business or a Commercial Antibody Evolution Business during the term of this Agreement; provided, however, that, with respect to any variable domains in-licensed as provided in Section 2.6, as long as XOMA retains any rights it may have
with respect to the discovery of such variable domains, a Third Party engaged in a Commercial Antibody Phage Display Business or a Commercial Antibody Evolution Business may be an AFFIMED Collaborator with respect to such Tandab or Flexibody
pursuant to Section 2.6. 
 1.3. “AFFIMED Field” means (a) with respect to the rights granted in
Section 2.1, Research; (b) with respect to the rights granted in Section 2.5(a)(i), the diagnosis, treatment, prevention or prophylaxis of any human condition or disease; and (c) with respect to the rights granted in
Section 2.5(a)(ii), production in E. Coli, but not the commercialization of any composition of matter or article of manufacture so produced. The AFFIMED Field shall not include any Non-Approved Uses. 

1.4. “AFFIMED Patent Rights” means the patent applications and patents listed on Schedule 1.4 hereto and, solely to
the extent any Valid Claim would cover or be included in the license grants provided for herein, all divisions, continuations, continuations-in-part, applications claiming priority thereto, and substitutions thereof; all foreign patent applications
corresponding to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any patents or patent applications, whether now existing or obtained in
the future, owned or controlled by AFFIMED containing a claim that is dominating over the foregoing patent rights (i.e., is necessarily infringed by the practicing of a claim in one of the foregoing applications or through the making, using,

  
 -2- 

 
exporting or importing Antibody Phage Display Materials or using Antibody Phage Display); and (iii) any patents or patent applications covered by any AFFIMED Third Party Licenses. 

1.5. “AFFIMED Product” means either a Flexibody or a Tandab manufactured in a prokaryote and containing a Licensed
Immunoglobulin. 
 1.6. “AFFIMED Technology” means the AFFIMED know how to create antibody libraries under the AFFIMED
patent rights. 
 1.7. “AFFIMED Third Party Licenses” means those license agreements between AFFIMED and any Third Party
relating to the subject matter of Article 4 of this Agreement, a list of which is set forth on Schedule 1.7, and such list shall be updated by AFFIMED from time to time. 

1.8. “Antibody Evolution” means the purposeful and/or guided alteration, either by random mutation or other means, of one or
more characteristics or attributes of an antibody and shall include, without limitation, directed mutagenesis, directed evolution or humanization of an Immunoglobulin. 

1.9. “Antibody Phage Display” means the use of Antibody Phage Display Materials, including, without limitation, to conduct
Research. 
 1.10. “Antibody Phage Display Materials” means (i) any collection or library of polynucleotide sequences
which encodes at least one Immunoglobulin and which is contained in bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or (ii) any collection or library of bacteriophage wherein an Immunoglobulin
is expressed as a fusion protein comprising an Immunoglobulin or at least a functionally operating region of an antibody variable region and an outer surface polypeptide of a bacteriophage. For the avoidance of doubt, and without limiting the
definition thereof, specifically excluded from the definition of Antibody Phage Display Materials are any article of manufacture or composition of matter suitable for display, expression or secretion of an Immunoglobulin in or from any organism or
system other than bacteria. With respect to AFFIMED, the term “Antibody Phage Display Materials” shall only include such materials or compositions of matter created by and under the exclusive control of Affimed Therapeutics AG and shall
not extend to any materials created by or under the control of any Third Party. 
 1.11. “Change in Control” means, with
respect to Affimed Therapeutics AG or XOMA Ltd., any transaction or series of transactions as a result of which any person or group (as defined under the U.S. Securities Exchange Act of 1934, as amended) becomes, directly or indirectly, the
beneficial owner of more than fifty percent (50%) of the total voting power of such entity’s equity securities or otherwise gains control of such entity, provided, however, that for the purposes of this definition, a “Change of
Control” shall not be deemed to occur upon the issuance or transfer of a controlling interest in the outstanding or issued stock of Affimed Therapeutics AG to bona fide financial investors who hold and control the stock solely for
investment purposes. 

  
 -3- 

 1.12. “Commercial Antibody Evolution Business” means, with respect to protein or
other evolution services, libraries, Immunoglobulins or materials, the out-licensing, commercial manufacture, sale, offer for sale, import for sale or export for sale of such protein or other evolution services, libraries, Immunoglobulins and
materials, including, without limitation, the sale of Antibody Evolution services. 
 1.13. “Commercial Antibody Phage Display
Business” means, with respect to immunoglobulin or antibody phage display services, libraries, Immunoglobulins or materials, the out-licensing, commercial manufacture, sale, offer for sale, import for sale or export for sale of such
immunoglobulin or antibody phage display services, libraries, Immunoglobulins and materials. 
 1.14. “Confidential
Information” means any proprietary or confidential information or material disclosed by a party to the other party pursuant to this Agreement, which is (a) disclosed in tangible form hereunder and is designated thereon as
“Confidential” at the time it is delivered to the receiving party, or (b) disclosed orally hereunder and identified as confidential or proprietary when disclosed and such disclosure of confidential information is confirmed in writing
within thirty (30) days by the disclosing party. 
 1.15. “Dispose” means to transfer, assign, lease, or in any other
fashion dispose of control, ownership or possession, but shall not mean to license or sell. “Disposition” shall have the correlative meaning. 

1.16. “Direct AFFIMED Cost(s)” means those actual out-of-pocket costs incurred by AFFIMED that directly and specifically
relate to those activities undertaken solely on behalf of XOMA pursuant to a XOMA Library Project. In determining “Direct AFFIMED Costs” chargeable under this Agreement, AFFIMED shall establish and use a reasonable project accounting
system and shall submit such system and any related methodologies for review and approval by XOMA. Each year, AFFIMED and XOMA shall agree on an applicable full time equivalent rate to be applied for the purposes of this definition; provided,
however, that such rate shall in no event be any greater than *****. Notwithstanding anything in this Section 1.16 to the contrary, only those Direct AFFIMED Costs contemplated by the applicable XOMA Library Project or otherwise approved by
XOMA shall be included in the definition of Direct AFFIMED Costs. Specifically excluded from the definition of Direct AFFIMED Cost are any amounts partially allocable to other projects or activities (internal or otherwise) other than a XOMA Library
Project, as the case may be, including without limitation overhead costs, capital charges, health and welfare benefit charges, heat, electricity, excess capacity and/or process or development work on materials or methods used in a XOMA Library
Project that also have general applicability to AFFIMED’s other activities. 
 1.17. “First Commercial Sale” means the
initial transfer by AFFIMED (either directly or through a Third Party, including without limitation any joint venture or similar arrangement in which AFFIMED or an AFFIMED Collaborator is a participant) of an Immunoglobulin subject to
Section 2.5(b) for value and not for demonstration, testing or promotional purposes. 

  
 -4- 

 1.18. “Flexibody” means a multimeric Fv-antibody, wherein each monomer of the
Fv-antibody comprises the following features: i) two neighboring variable domains that form an antigen-binding ***** ScFv unit; these two, first and second, variable domains are linked by a peptide linker of at least ***** amino acid residues; and
ii) two other neighboring variable domains that are non-covalently bound to two variable domains of another monomer of the Fv-antibody resulting in the formation of two additional antigen binding sites to form the multimerization motif; these two,
third and fourth, variable domains of each monomer are linked by a peptide linker consisting of a maximum of ***** amino acid residues. 

1.19. “Immunoglobulin subject to Section 2.5(b)” means any composition of matter or article of manufacture, including
without limitation any diagnostic, prophylactic or therapeutic Immunoglobulin as to which AFFIMED elects to exercise its option right pursuant to Section 2.5(b), which (a) contains a Licensed Immunoglobulin; or (b) was discovered or
created by, arose out of or is related to the conduct of Research and/or use of a Licensed Immunoglobulin or Licensed Immunoglobulin Information; or (c) was discovered or is sold by or on behalf of AFFIMED or an AFFIMED Collaborator under
conditions which constitute utilization of the XOMA Patent Rights or use of the XOMA Know-How; or (d) is an Immunoglobulin as to which AFFIMED, on its own behalf, intends to manufacture in E. Coli, but as to which it does not wish to
obtain a license under Section 2.5(a)(i). 
 1.20. “Immunoglobulin” means any molecule, including without limitation
whole length immunoglobulin molecules (e.g., IgG, IgM, IgE, IgA and IgD molecules) and ScFv, Fv and Fab molecules, that has an amino acid sequence by virtue of which it specifically interacts with an antigen and wherein that amino acid
sequence consists essentially of a functionally operating region of an antibody variable region, including without limitation any naturally occurring or recombinant form of such a molecule. 

1.21. “Licensed Immunoglobulin” means any Immunoglobulin discovered, isolated or characterized by AFFIMED through the use of
Licensed Materials, use of the XOMA Know-How, bacterial expression of a polypeptide, or use of any composition of matter claimed in, created by or involving the utilization of any method claimed in any Valid Claim of the XOMA Patent Rights. 

1.22. “Licensed Immunoglobulin Information” means any data, know-how or other information relating, concerning or pertaining
to a Licensed Immunoglobulin, including, without limitation, data, know-how or other information characterizing or constituting such Licensed Immunoglobulin’s polynucleotide or amino acid sequence, purported function or utility, antigen binding
affinity, or physical or biochemical properties. 
 1.23. “Licensed Materials” means (a) any polynucleotide sequences
created by and under the exclusive control of AFFIMED encoding an Immunoglobulin; (b) any 

  
 -5- 

 
expression vector created by or under the exclusive control of AFFIMED which encodes an Immunoglobulin; or (c) any Antibody Phage Display Materials created by and under the exclusive control
of AFFIMED. For the avoidance of doubt, and without expanding the definition thereof, specifically excluded from the definition of Licensed Materials is any article of manufacture or composition of matter (i) made or used by a third party;
(ii) constituting or useful for the display of Immunoglobulins in any organism other than bacteria; or (iii) created by or under the control of any of the entity engaged in the licensing, manufacture, sale, offer for sale, import or export
of antibody phage display services, Immunoglobulin or materials. 
 1.24. “Net Sales” means, with respect to sales by
AFFIMED and/or an AFFIMED Collaborator (either directly or through a Third Party, including without limitation any joint venture or similar arrangement in which such an entity is a participant), the gross amount invoiced by AFFIMED and/or an AFFIMED
Collaborator (or such joint venture or similar arrangement) to an independent Third Party less the following items: 
  

	 	(a)	Trade, cash and quantity discounts actually allowed and taken directly with respect to such sales; 

  

	 	(b)	Excises, sales taxes or other taxes imposed upon and paid directly with respect to such sales (excluding national, state or local taxes based income); 

 

	 	(c)	Amounts repaid or credited by reason of rejections, defects, recalls or returns or because of rebates or retroactive price reduction; and 

 

	 	(d)	Freight, transportation and insurance. 

 1.25. “Non-Approved Uses” means any
and all uses not directly related to the AFFIMED Field and shall expressly include (a) catalog or on-line sales of cloning or expression vectors, reagents or research or commercial kits; (b) expression of peptides or polypeptides,
including Immunoglobulins or binding fragments thereof, on cell surfaces or viral surfaces; (c) identification, selection or expression of proteins, reagents, and/or enzymes or compositions of matter for purely industrial uses or which are
useful in the chemical industry and/or industrial manufacturing processes, including, without limitation, the identification selection or expression of catalytic antibodies; (d) plant science or agricultural applications; and
(e) veterinary or animal health applications. 
 1.26. “Research” means the identification, selection, isolation
purification, characterization, study and/or testing of Immunoglobulins for any purpose, including, without limitation the discovery and development of human therapeutics or diagnostics and shall include Antibody Phage Display using Licensed
Materials. Included within the definition of “Research” shall be all in vitro screening or assays customarily performed in pre-clinical research. In the case of AFFIMED, “Research” shall not include (a) any effort to obtain
economic value from a Third Party, including, without limitation, from licensing to a Third Party any composition of matter or article of manufacture or any Licensed Immunoglobulin Information; or (b) commercial or industrial manufacture or any
activities solely directed to the creation of such capacities. 

  
 -6- 

 1.27. “Research Quantities” means those quantities of an Immunoglobulin
reasonably required for Research purposes. 
 1.28. “Tandab” means a bispecific tetravalent homodimeric single chain
antibody formed by the dimerisation of a single gene product comprising the heavy and light variable domains of two antibodies, A and B. The order of the domains from the N-terminus can be either AH-BL-BH-AL
or AL-BH-BL-AH. 
 1.29. “Third Party” means any person or entity other than AFFIMED or XOMA. 

1.30. “Valid Claim” means (i) a claim of an issued and unexpired patent included within the AFFIMED Patent Rights or the
XOMA Patent Rights, as the case may be, which has not been held invalid in a final decision of a court of competent jurisdiction from which no appeal may be taken, and which has not been disclaimed or admitted to be invalid or unenforceable through
reissue or otherwise, or (ii) a claim of a pending patent application within the AFFIMED Patent Rights or the XOMA Patent Rights, as the case may be. 

1.31. “XOMA Development Partner” means a Third Party from whom XOMA either in-licenses a target for development and/or
commercialization or with whom XOMA shares the economic risk of development or commercialization of a target or Immunoglobulin being developed or commercialized on behalf of XOMA. 

1.32. “XOMA Know-How” means unpatented and/or unpatentable technical information, including ideas, concepts, inventions,
discoveries, data, designs, formulas, specifications, procedures for experiments and tests and other protocols, results of experimentation and testing, fermentation and purification techniques, and assay protocols, whether now existing or obtained
in the future (but as to future know-how, only as it relates to the materials transferred to AFFIMED pursuant to Section 2.2 hereof), owned by XOMA which XOMA has the right to license or sublicense and which may be necessary for the practice of
the XOMA Patent Rights or which would be misappropriated by the activities of AFFIMED, the AFFIMED Collaborators or the Development Partners of AFFIMED contemplated hereunder with respect to the materials transferred pursuant to Section 2.2
hereof but for this Agreement. XOMA Know-How shall not include the XOMA Patent Rights. All XOMA Know-How shall be confidential information of XOMA. 

1.33. “XOMA Licensee” means any third party to which XOMA grants or transfers any rights in respect of any composition of
matter or article of manufacture or a third party from whom XOMA in-licenses a target or Immunoglobulin, with whom XOMA collaborates to develop an Immunoglobulin, or who is working with or on behalf of XOMA. 

  
 -7- 

 1.34. “XOMA Patent Rights” means the patent applications and patents listed on
Schedule 1.34 hereto and, solely to the extent any Valid Claim would cover or be included in the license grants provided for herein, all divisions, continuations, continuations-in-part, applications claiming priority thereto, and
substitutions thereof; all foreign patent applications corresponding to the preceding applications; all U.S. and foreign patents issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any patents or
patent applications, whether now existing or obtained in the future, owned or controlled by XOMA containing a claim that is dominating over the foregoing patent rights (i.e., is necessarily infringed by the practicing of a claim in one of the
foregoing applications). 
 1.35. Additional Defined Terms. The following terms are defined in the corresponding sections indicated
below: 
  

			
	 Term
	  	 Section

	Arbeitnehmererfindungsgesetz	  	5.4(b)
	Deliverables	  	6.l(b)
	Existing Materials	  	9.4(d)
	ICDR	  	10.13(a)
	In-License Request	  	2.6
	Option	  	2.5(a)
	Project Materials	  	5.4(a)
	Records	  	2.8(b)
	Research License	  	2.1
	Services	  	6.1(a)
	Title XI	  	10.9
	Transferred Materials	  	2.4(a)
	Work Plan	  	6.l(b)
	XOMA Authorized Site	  	2.7
	XOMA Library	  	5.1(a)
	XOMA Library Project	  	5.l(a)
	XOMA Library Specification	  	5.l(a)

 1.36. Interpretation 

(a) Whenever any provision of this Agreement uses the term “including” (or “includes”), such term shall be deemed to mean
“including without limitation” and “including but not limited to” (or “includes without limitations” and “includes but is not limited to”) regardless of whether the words “without limitation” or
“but not limited to” actually follow the term “including” (or “includes”); 
 (b) The recitals set forth at
the start of this Agreement, along with the Schedules to this Agreement, and the terms and conditions incorporated in such recitals and Schedules shall be deemed integral parts of this Agreement and all references in this Agreement to this Agreement
shall encompass such recitals and Schedules and the terms and conditions incorporated in such recitals and Schedules; 

  
 -8- 

 (c) Unless otherwise provided, all references to Sections, Articles and Schedules in this
Agreement are to Sections, Articles and Schedules of and to this Agreement; 
 (d) All references to days, months, quarters or years are
references to calendar days, calendar months, calendar quarters or calendar years; and 
 (e) The above definitions are intended to
encompass the defined terms in both the singular and plural forms. 
 ARTICLE 2 

XOMA GRANT OF RIGHTS TO AFFIMED 

2.1. Research License. XOMA hereby grants to AFFIMED a worldwide, fully paid-up, royalty free, non-exclusive, non-transferable license,
on its own behalf and on behalf of an AFFIMED Collaborator, and without the right to sublicense, under the XOMA Patent Rights and the XOMA Know-How to make and use Licensed Materials to conduct Research, including Antibody Phage Display (the
“Research License”). For the sake of clarity, the Research License is personal to AFFIMED and is to be used on behalf of any AFFIMED Collaborator only in respect of or in connection with the activities that such AFFIMED Collaborator
is engaged in that are the basis for meeting the definition of AFFIMED Collaborator and not any other activities. It is understood between the Parties that the license granted by this Section 2.1 is a “research only” license and that,
unless and until the Option is exercised in accordance with Section 2.5(a), AFFIMED shall have no rights to commercialize, either directly or indirectly, any immunoglobulin or Licensed Immunoglobulin Information, arising from the activities
subject to this license grant. 
 2.2. XOMA Transfer to AFFIMED. Within thirty (30) days of the Effective Date, XOMA shall
transfer to AFFIMED, at a mutually agreed place and time, the materials identified on Schedule 2.2. For the avoidance of doubt, such materials shall constitute XOMA Know-How. Technology is included in the initial consideration to XOMA under
this Agreement and includes up to two person-days of XOMA scientific staff time at XOMA’s facilities for up to two (2) AFFIMED employees within 9 months from the Effective Date (which period may be extended by mutual consent of the
parties, which consent shall not be unreasonably withheld). Thereafter, AFFIMED will be able to consult with XOMA scientific staff at $1,500/person-day (based on an eight hour day) beyond the two person-days. 

2.3. No Implied Rights. Only the rights and licenses granted pursuant to the express terms of this Agreement shall be of any legal
force or effect. No license or other rights shall be deemed to have been granted to AFFIMED or an AFFIMED Collaborator other than as expressly provided for in this Agreement. For the avoidance of doubt, the grants of rights made pursuant to
Section 2.1 and, upon exercise of the Option, Section 2.5, do not include, and expressly exclude, the following: 
  

	 	(a)	any right or license to engage in any activities on behalf of or in collaboration with any Third Party, other than an AFFIMED Collaborator; 

  
 -9- 

	 	(b)	except upon proper exercise of the Option with respect to each Licensed Immunoglobulin, any right or license to make or have made any amount, other than Research Quantities, of a Licensed Immunoglobulin by practicing
the XOMA Patent Rights or the XOMA Know-How; 

  

	 	(c)	any release or right to release any Third Party, including an AFFIMED Collaborator, from any claim of infringement under the XOMA Patent Rights or misappropriation of the XOMA Know-How; 

 

	 	(d)	does not constitute a release or waiver of past, present or future infringement of the XOMA Patent Rights or misappropriation of the XOMA Know-How by AFFIMED or any Third Party; 

 

	 	(e)	any right or license under the XOMA Patent Rights or XOMA Know-How to sell, lease, license, transfer or dispose of the ownership or possession to a Third Party of any composition of matter or article of manufacture
suitable for the conduct of Antibody Evolution or Antibody Phage Display; and/or 

  

	 	(f)	any right or license to cause any Third Party to use Antibody Phage Display Materials to identify, select, characterize, study or test a polypeptide, including but not limited to an Immunoglobulin. 

2.4. Transfer Restrictions. 

(a) AFFIMED shall not (i) undertake any Research activities, including any Antibody Phage Display, on behalf of a Third Party or
(ii) Dispose of a Licensed Immunoglobulin, Licensed Immunoglobulin Information or any Immunoglobulin arising out of the practice of any method within the scope of the XOMA Patent Rights (“Transferred Materials”) to any Third
Party until (in the case of either clause (i) or clause (ii)) such time as it has provided to such Third Party the redacted copy of this Agreement referred to in Section 7.2 and the form of notice set out at Schedule 2.4. 

(b) AFFIMED shall enter into a written arrangement with any Third Party with respect to any activities as to which it or such Third Party does
or intends to claim the benefits of any of the licenses or other grants provided for in this Article 2, and such written arrangement shall contain provisions (i) pursuant to which the recipient of any Transferred Materials agrees to abide by
each of the limitations, restrictions and other obligations provided for by this Agreement, including without limitation the restrictions on use of Transferred Materials for purposes other than Research and the obligations of Section 2.5(b);
(ii) implementing a covenant not to use Transferred Materials for any purpose other than for Research purposes otherwise authorized by this Agreement; (iii) providing that the “first sale” doctrine does not apply to any
Disposition; and (iv) permitting an AFFIMED Collaborator to further Dispose of Transferred Materials only to a Third Party who otherwise meets the definition of an AFFIMED Collaborator and who 

  
 -10- 

 
executes a written agreement in which it undertakes all of the obligations applied to the transferring party. XOMA shall be, and the agreements subject to this Section 2.4 shall provide that
XOMA shall be, an intended third party beneficiary with respect to the foregoing provisions. 
 2.5. License Option. 

(a) So long as the provisions of Section 2.5(b) are complied with and AFFIMED and, as applicable, any AFFIMED Collaborator, is not
otherwise in breach of any material provision of this Agreement, upon ***** prior written notice, on an Immunoglobulin by Immunoglobulin basis, XOMA hereby agrees to grant (the “Option”) a worldwide, non-exclusive, non-transferable
license to AFFIMED, on its own behalf and on behalf of an AFFIMED Collaborator, under the XOMA Patent Rights and the XOMA Know-How in the AFFIMED Field to: 
  

	 	(i)	make or have made (in a prokaryote and without use of a discistronic construct), use, sell, offer to sell, import and otherwise commercialize those Licensed Immunoglobulins discovered, isolated or optimized under the
Research License and as to which AFFIMED or the AFFIMED Collaborator pays the amounts, including royalties on Net Sales, due under Article 3; and/or 

  

	 	(ii)	to make in E. Coli, solely on its own behalf, clinical and commercial supplies of any Immunoglobulin discovered or isolated exclusively by AFFIMED or by AFFIMED on behalf of an AFFIMED Collaborator and as to
which AFFIMED pays the amounts, including royalties on Net Sales, due under Article 3. 

 XOMA shall not be obligated to grant the license
provided for in this Section 2.5(a) unless the other provisions of this Agreement, including Section 2.5(b), are complied with. 

(b) For each Licensed Immunoglobulin as to which AFFIMED wishes to obtain a license pursuant to Section 2.5(a), AFFIMED shall provide to
XOMA a written notice which identifies the specific Immunoglobulin for which AFFIMED seeks such a license, the target to which such Immunoglobulin binds, a designation as to whether such Immunoglobulin was discovered or isolated pursuant to the
Research License, a written certification that AFFIMED or as applicable an AFFIMED Collaborator, for each Licensed Immunoglobulin, has complied with all of the provisions of this Agreement and a notification as to whether AFFIMED seeks a license
pursuant to Section 2.5(a)(i), Section 2.5(a)(ii) or both. Upon receipt of such written notice, XOMA shall, pursuant to its then most current standard non-economic terms, grant the applicable license, unless (i) such Immunoglobulin or
target is the subject of an exclusive license granted by XOMA to a Third Party or (ii) XOMA has contemporaneous written proof of a bona fide development program with respect to any Immunoglobulin binding to the same target as the Immunoglobulin
as to which the request for license grant has been made. 

  
 -11- 

 (c) Upon the successful exercise of an Option to an Immunoglobulin, for so long as the applicable
royalty and other payments are made, XOMA covenants that it shall not initiate or permit any Third Party over whom it has control to initiate or assist in any way in the initiation or prosecution of any action asserting a claim of infringement under
the XOMA Patent Rights or misappropriation of the XOMA Know-How against AFFIMED or any AFFIMED Collaborator to the extent reasonably necessary to permit the authorized making, having made, use, sale, offer for sale or commercialization of any
Licensed Immunoglobulin subject to a grant under Section 2.5(a)(i) and the making and having made of any Immunoglobulin subject to a grant under Section 2.5(a)(ii). The covenant not to sue provided by this Section 2.5(c): 

 

	 	(i)	shall become void and without effect as to any entity or person who claims its benefit but fails to materially discharge or comply with any term of its written agreement with AFFIMED provided for in Section 2.4(b);

  

	 	(ii)	is personal to AFFIMED and any such AFFIMED Collaborator and cannot be assigned or transferred; 

  

	 	(iii)	as to any AFFIMED Collaborator, does not extend to making, using, selling, having made or importing Antibody Phage Display Materials or any compositions of matter or articles of manufacture suitable for Antibody Phage
Display; and 

  

	 	(iv)	does not constitute a release or waiver of past, present or future infringement of the XOMA Patent Rights or misappropriation of the XOMA Know-How by AFFIMED or any Third Party, including, without limitation, any
AFFIMED Collaborator acting outside of the scope of the written agreement with AFFIMED provided for in Section 2.4(b). 

(d) AFFIMED covenants not to commercialize, license or develop any Immunoglobulin discovered under the Research License without submitting
such Immunoglobulin to XOMA for a license pursuant to this Section 2.5. 
 2.6. Third Party Variable Domains. (a) From time
to time, but no more often than once per quarter, AFFIMED may, on its own behalf or on behalf of a Third Party who otherwise qualifies as an AFFIMED Collaborator and who will be an AFFIMED Collaborator if the other provisions of this
Section 2.6 are met, request in writing that XOMA permit AFFIMED to format a variable domain not discovered by AFFIMED into a Tandab or a Flexibody and, as applicable, exercise its Option rights pursuant to Section 2.5(a)(i) and (ii). Such
writing (the “In-License Request”) shall specify: (i) the potential AFFIMED Collaborator and any Third Party with a financial interest in the variable domains or the proposed AFFIMED Product; (ii) the variable domains;
(iii) the target as to which such variable domains are directed; (iv) whether the Option request extends to the rights provided for by Sections 2.5(a)(i), 2.5(a)(ii) or both; (v) the format such variable domains shall be
converted into (Tandab or Flexibody); and (vi) a statement as to whether, to the knowledge of AFFIMED after diligent investigation, such variable domains were discovered, identified, characterized, optimized and/or altered using the

  
 -12- 

 
XOMA Patent Rights or bacterial expression, including without limitation via Antibody Phage Display. Upon such request, and until the end of Phase II (or equivalent) clinical trials, such Tandab
or Flexibody shall be deemed to be an “AFFIMED Product” under this Agreement, provided, however, that if no In-License Request is made prior to initiation of Phase II or if a license is not subsequently consummated, then any status
as an AFFIMED Product shall, retroactively, be cancelled and the Tandab or Flexibody will be deemed as to have never been licensed under this Agreement. 

(b) Within ***** of the receipt of the In-License Request, XOMA, pursuant to the same conditions as Section 2.5(b), shall, in writing,
indicate whether each such proposed AFFIMED Product is accepted to be a Licensed Immunoglobulin. For each such proposed AFFIMED Product accepted as a Licensed Immunoglobulin, the following conditions shall apply: (i) XOMA, AFFIMED and the Third
Party must agree to the form of and execute a written license agreement under which XOMA shall grant, pursuant to its then most current non-economic terms, the applicable license; (ii) AFFIMED and the Third Party, if applicable, must negotiate
in good faith for and pay cash consideration to XOMA to obtain a release for any past infringement of the XOMA Patent Rights by such Third Party; and (iii) such license shall, as applicable, contain licenses or grants to XOMA and any XOMA
Development Partner or XOMA Licensee under those rights as may be under the control of or sublicenseable from such Third Party in a form equivalent to the license grant and rights given by AFFIMED to XOMA pursuant to Article 4 of this Agreement.

 (c) AFFIMED’s rights under this Section 2.6 shall apply to no more than five (5) different Tandabs or Flexibodies. 

2.7. XOMA Authorized Site. AFFIMED may “have made” Licensed Immunoglobulins or Immunoglobulins subject to
Section 2.5(a)(ii) under the XOMA Patent Rights and the XOMA Know-How in the AFFIMED Field at a XOMA Authorized Site. All activities at a XOMA Authorized Site in the AFFIMED Field shall be pursuant to a contract manufacturing agreement
containing all of the applicable provisions of this Agreement and shall be for the sole benefit of AFFIMED. XOMA shall be provided a reasonable opportunity prior to execution of any such agreement to review a redacted version of such agreement that
is sufficient to confirm the foregoing obligations, and AFFIMED shall give due consideration to any comments of XOMA thereon. Prior to permitting or initiating any activity at a XOMA Authorized Site in the AFFIMED Field, AFFIMED covenants that such
XOMA Authorized Site shall (i) agree in advance in writing to be bound for the benefit of XOMA by all of the provisions of this Agreement; (ii) agree to implement such customary and usual safeguards as may be necessary to insure that the
XOMA Know-How is accessed and utilized on a “need to know” basis only; and (iii) agree that such XOMA Authorized Site shall undertake the activities solely on behalf of AFFIMED and as a result of such activities shall not claim any
license or right under the XOMA Patent Rights or XOMA Know-How for the benefit of itself or any other Third Party. AFFIMED shall remain fully and primarily liable for all actions of, or failures to act by, such XOMA Authorized Site in connection
therewith and agrees to hold XOMA harmless with respect thereto without qualification. For the avoidance of doubt, AFFIMED acknowledges that no such delegation of rights shall relieve AFFIMED 

  
 -13- 

 
of its responsibilities for performance of any of its obligations hereunder. For the purposes of this Section 2.7, a “XOMA Authorized Site” shall mean one or more contract
manufacturers designated in writing from time to time by XOMA. The terms and conditions of any agreement between XOMA and the XOMA Authorized Site shall also apply to any activities undertaken on behalf of AFFIMED pursuant to this Section 2.7.
No such entity or person shall be deemed to be a XOMA Authorized Site unless and until, as to each Licensed Immunoglobulin or Immunoglobulin subject to Section 2.5(b), as applicable, to be produced pursuant to this Section 2.7, it enters
into a legally binding agreement with AFFIMED that implements the provisions of this Section 2.7, naming XOMA as a third party beneficiary of those provisions of such agreement that pertain to confidentiality and restrictions on transfer and
use of Licensed Immunoglobulins, XOMA Patent Rights and XOMA Know-How provided for in this Agreement. 
 2.8. Reports, Records and
Audits. 
 (a) ***** after the end of each calendar quarter, commencing with the first calendar quarter commencing after the Effective
Date, AFFIMED shall deliver to XOMA a written report which shall specify the name, address and contact person for each and every potential and actual AFFIMED Collaborator and any person or entity with whom AFFIMED has engaged in Research, who has
received any Transferred. Materials or, in the case of the exercise of the Option in accordance with Section 2.5(a), who has received any clinical or commercial supplies manufactured by AFFIMED or with whom AFFIMED is engaged in the
commercialization of an immunoglobulin subject to the Option of Section 2.5(a). The reports delivered by AFFIMED to XOMA pursuant to this Section 2.8(a) shall be Confidential Information of AFFIMED. 

(b) AFFIMED shall maintain records fully and properly reflecting those activities to be reported to XOMA pursuant to Section 2.8(a) (the
“Records”), in sufficient detail and in good scientific manner appropriate for patent, regulatory and manufacturing purposes for at least three (3) years. Upon the written request of XOMA and not more than once in each calendar
year, AFFIMED shall permit an independent consultant appointed by XOMA and subject to customary confidentiality restrictions, at XOMA’s expense, to have access during normal business hours to such of the records of AFFIMED as may be reasonably
necessary to verify compliance with the terms of this Agreement, as well as the accuracy of the reports hereunder. AFFIMED shall certify any statements by AFFIMED personnel as to their accuracy and correctness. 

2.9. Ownership; Enforcement. At all times XOMA will retain ownership of the XOMA Know-How and the XOMA Patent Rights and may use and
commercialize such XOMA Know-How and XOMA Patent Rights itself or with any Third Party. XOMA retains the right, at its sole discretion, to enforce, maintain and otherwise protect the XOMA Know-How and the XOMA Patent Rights. In addition to the
requirements of Section 2.8, AFFIMED shall give XOMA prompt notice of misappropriation of any of the XOMA Know-How, or any infringement of any of the XOMA Patent Rights, by a Third Party which comes to AFFIMED’s attention during the term
of this Agreement. 

  
 -14- 

 2.10. No Admission of Infringement. The execution of this Agreement is not an admission
that any action by AFFIMED or AFFIMED Product either infringed or is infringing the XOMA Patent Rights and AFFIMED reserves all of its rights with respect to the practice of any technology and the production of any composition of matter or article
of manufacture unrelated to the XOMA Patent Rights or the XOMA Know-How. 
 ARTICLE 3 

PAYMENTS 
 3.1. Milestone
Payments. 
 (a) COMMERCIALIZATION LICENSE. For each Licensed Immunoglobulin as to which an Option is exercised pursuant to
Section 2.5(a)(i), within ***** following the achievement by AFFIMED or an AFFIMED Collaborator of the following milestones with respect to each such Immunoglobulin AFFIMED or the AFFIMED Collaborator shall pay to XOMA the applicable payments
below: 
  

					
	 Event
	  	Payment	 
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  

 (b) PRODUCTION LICENSE. For each Immunoglobulin, including, as applicable, each Licensed Immunoglobulin, as to
which an Option is exercised pursuant to Section 2.5(a)(ii), within ***** following the achievement by AFFIMED with respect to each such Immunoglobulin AFFIMED or the AFFIMED Collaborator shall pay, in addition to amounts owed, if any, under
Section 3.1(a), to XOMA the applicable payments below: 
  

					
	 Event
	  	Milestone	 
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  
		
	 *****
	  	 	*****	  

 3.2. Royalties. With respect to any Immunoglobulin subject to Section 2.5(b) as to which an Option
is exercised and a license taken under Section 2.5(a)(i), but not as to which an Option is exercised and a license taken under Section 2.5(a)(ii), AFFIMED 

  
 -15- 

 
or the applicable AFFIMED Collaborator shall pay to XOMA a royalty in cash equal to ***** of the Net Sales by or on behalf of AFFIMED or such AFFIMED Collaborator of any such Immunoglobulin in
each calendar quarter, commencing with the first calendar quarter ending after the Effective Date. 
 (a) With respect to any Immunoglobulin
subject to Section 2.5(b) as to which an Option has been exercised and a license taken under Section 2.5(a)(ii), but not as to which an Option and a license taken under Section 2.5(a)(i), AFFIMED shall pay to XOMA a royalty in cash
equal to ***** of the Net Sales by or on behalf of AFFIMED of any such Immunoglobulin in each calendar quarter, commencing with the first calendar quarter ending after the Effective Date. 

(b) With respect to any Immunoglobulin subject to Section 2.5(b) as to which an Option has been exercised and a license taken under both
Sections 2.5(a)(i) and 2.5(a)(ii), AFFIMED shall pay to XOMA a royalty in cash equal to ***** of the Net Sales by or on behalf of AFFIMED of any such Immunoglobulin in each calendar quarter, commencing with the first calendar quarter ending after
the Effective Date. 
 (c) Royalties shall be payable on a country-by-country and Immunoglobulin by Immunoglobulin basis from the First
Commercial Sale of such Immunoglobulin (or any composition of matter or article of manufacture comprising or containing such Immunoglobulin) until the expiration of the last-to-expire XOMA Patent Right in such country with respect to which a Valid
Claim covers the manufacture, use, sale, offer for sale, import or export of such Product or the tenth (10th) anniversary of such First Commercial Sale, whichever is later. 

3.3. Payments; Currency. All payments due hereunder shall be paid by wire transfer in United States dollars in immediately available
funds to an account designated by XOMA. Payments required pursuant to Section 3.1 hereof shall be due and payable to XOMA when the corresponding milestone is achieved and shall be paid within thirty (30) days thereof Payments required
pursuant to Section 3.2 hereof shall be due and payable to XOMA when the corresponding Net Sales are received by AFFIMED, the AFFIMED Collaborator, or any Joint Venture in which AFFIMED is a participant and shall be paid within sixty
(60) days of the end of each calendar quarter. If any currency conversion shall be required in connection with the payment of any royalties hereunder, such conversion shall be made by using the exchange rate for the purchase of U.S. dollars
quoted in the U.S. version of the Wall Street Journal on the last business day of the calendar quarter to which such payments relate. 

3.4. Payment Reports. AFFIMED shall make a written report to XOMA within ***** of the achievement of each of the milestones set forth
in Section 3.1, stating in each such report the Licensed Immunoglobulin or Immunoglobulin to which such milestone relates and the specific milestone achieved, including the relevant agency or other regulatory body. After the First Commercial
Sale of a Licensed Immunoglobulin or Immunoglobulin subject to Section 2.5(b) on which royalties are required to be paid hereunder, AFFIMED shall make quarterly written reports to XOMA 

  
 -16- 

 
within ***** after the end of each calendar quarter, stating in each such report, the description and aggregate Net Sales of each Licensed Immunoglobulin or Product sold during the calendar
quarter. XOMA shall treat all such reports as Confidential Information of AFFIMED Concurrently with the making of such reports, AFFIMED or, as applicable, the AFFIMED Collaborator, shall pay XOMA the amounts specified in Sections 3.1 and 3.2 hereof.

 3.5. Payment Records and Inspection. AFFIMED and each AFFIMED Collaborator shall keep complete, true and accurate books of account
and records for the purpose of determining the amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of AFFIMED for at least ***** following the end of the calendar quarter to which they
pertain. Upon the written request of XOMA and not more than once in each calendar year, AFFIMED shall permit an independent consultant appointed by XOMA and reasonably acceptable to AFFIMED to have access during normal business hours to such of the
records as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any year ending not more than ***** prior to the date of such request. The consultant shall disclose to XOMA only the results and conclusions of its
review and the specific details concerning any discrepancies. No other information shall be shared by the consultant without the prior consent of AFFIMED unless disclosure is required by law, regulation or judicial order. Inspections conducted under
this Section 3.5 shall be at the expense of XOMA, unless an underpayment exceeding ***** of the amount stated for the full period covered by the inspection is identified, in which case all out-of-pocket costs relating to the inspection will be
paid promptly by AFFIMED. Any underpayments or unpaid amounts discovered by such inspections or otherwise will be paid promptly by AFFIMED, with interest from the date(s) such amount(s) were due at an annual rate equal to the lesser of the prime
rate reported by the Bank of America plus ***** or the highest interest rate permitted under applicable law. 
 3.6. Commercially
Reasonable Efforts. AFFIMED will use commercially reasonable efforts until clinical phase III to exploit the XOMA Patent Rights and maximize the amounts available to be shared with XOMA pursuant to this Article 3. 

ARTICLE 4 
 AFFIMED GRANT OF
RIGHTS TO XOMA 
 4.1. License Grants. AFFIMED hereby grants to XOMA, on its own behalf and on behalf of any XOMA Development Partner
or XOMA Licensee, a fully paid-up, non-exclusive, royalty-free, worldwide license or sublicense, as the case may be, under the AFFIMED Patent Rights, to engage in Research and to discover, isolate, optimize, develop, offer to use, use, offer for
sale, sell, make, have made, export and import Immunoglobulins or any product containing or comprising an Immunoglobulin. Included within the grants provided for by this Section 4.1, without limiting such grants shall be (a) the right to
make and use Antibody Phage Display Materials and to make, use, sell, offer for sale, import or export any composition of matter or article of manufacture arising out of the use of Antibody Phage Display Materials, including, without limitation

  
 -17- 

 
any XOMA Libraries), and (b) a fully paid-up, non-exclusive, royalty-free worldwide right and license under the AFFIMED Patent Rights to all uses of the Project Materials by itself or any
Third Party, including a XOMA Development Partner or XOMA Licensee and any data, materials, compositions of matter or articles of manufacture arising therefrom. XOMA is licensed hereby to use Antibody Phage Display Materials, including without
limitation display libraries, received from or used by any Third Party, free from any contractual obligations or limitations otherwise applicable thereto, so long as XOMA otherwise abides by the terms and conditions of this Agreement. Any use of
such phage display materials by XOMA shall be governed in all respects by the provisions of this Agreement and not the provisions of any agreements between AFFIMED and any Third Party. 

4.2. Limited Sublicense Rights. The rights granted pursuant to Section 4.1 shall include, but expressly as limited by this
Section 4.2, the right to grant sublicenses under the AFFIMED Patent Rights to the extent reasonably necessary for XOMA, on its own behalf, on behalf of a XOMA Licensee or XOMA Development Partner, to license, develop, commercialize or
otherwise enjoy the benefit of any Immunoglobulin or other composition of matter or article of manufacture discovered, isolated, characterized, or optimized by XOMA. For the avoidance of doubt, AFFIMED remains in the exclusive control of the AFFIMED
Technology .and insofar no rights are transferred by this Agreement to XOMA, a XOMA Licensee or a XOMA Development Partner. 
 4.3.
Covenant Not To Sue. AFFIMED covenants that it shall not initiate or permit any Third Party over whom it has control to initiate or assist in any way in the initiation or prosecution of any action asserting a claim of infringement under the
AFFIMED Patent Rights or misappropriation of the Project Materials against XOMA, a XOMA Development Partner, XOMA Licensee or any Third Party collaborating in the commercialization of any Immunoglobulin discovered, isolated, characterized,
optimized, developed or made by XOMA. For the avoidance of doubt, the covenant not to sue contained within this Section 4.3 shall include any and all claims that arise out of (a) the use by XOMA of any materials or services created by XOMA
or any Third Party, including a Third Party engaged in a Commercial Antibody Evolution Business or Commercial Antibody Phage Display Business; (b) utilization of the XOMA Patent Rights or use of the XOMA Know-How; and (c) use or transfer
of the Project Materials as permitted under the provisions of this Agreement. The covenant not to sue provided by this Section 4.3: 
  

	 	(a)	is personal to XOMA and, as applicable, any XOMA Development Partner and cannot be assigned or transferred; and 

  

	 	(b)	does not extend to activities conducted on behalf of any person or entity other than XOMA or its Development Partners. 

4.4. Maintenance of Third Party Licenses. AFFIMED shall maintain in full force and effect all of the Third Party Licenses. In the event
an event of default or termination occurs or if any such license is about to expire, AFFIMED shall provide prompt notice thereof to XOMA who shall, to the maximum extent possible, be 

  
 -18- 

 
permitted, on its own behalf, including, without limitation, by causing AFFIMED to cure or to extend the term of the applicable license, insure continuing rights under such licenses. 

ARTICLE 5 
 XOMA LIBRARY PROJECT

 5.1. AFFIMED Library Construction. 

(a) Under the terms and conditions of this Agreement and as described in Schedule 5.1, AFFIMED agrees to create (each a “XOMA
Library Project”) ***** libraries of antibody genes, and expression vectors encoding such antibody genes, derived from ***** samples (each a “XOMA Library”). At XOMA’s option and upon its written request, AFFIMED
shall create each XOMA Library in accordance with XOMA’s written instructions and specifications (each a “XOMA Library Specification”) by applying any technology then under AFFIMED’s control. Each XOMA Library
Specification shall provide reasonable detail setting forth the nature and characteristics of the XOMA Library to be constructed. For the avoidance of doubt, at XOMA’s request, the XOMA Library may be encoded in expression vectors, including
bacteriophage or phagemid display vectors of XOMA’s selection. Within thirty (30) days of the request by XOMA, at AFFIMED’s request, XOMA shall provide such written technical and other information that is reasonably necessary for
AFFIMED to assess the technical requirements for construction of the XOMA Library. 
 (b) Within sixty (60) days of the provision of
the XOMA Specification, AFFIMED shall provide in writing the anticipated timeline and a good faith estimate of the total Direct AFFIMED Costs required for construction of the applicable XOMA Library. Within thirty (30) days of the receipt of
such timeline and cost estimate, XOMA shall comment on and either approve or, after good faith negotiations with AFFIMED, modify and approve such timeline and cost estimate. At any time prior to the commencement of a XOMA Library Project, XOMA may
cancel such XOMA Library Project and such cancelled XOMA Library Project shall not be counted with respect to the other provisions of this Article 5. AFFIMED shall use commercially reasonable and diligent efforts to commence and complete the
activities necessary for the completion of the creation and transfer to XOMA of each XOMA Library with the same level of skill, resources and personnel as it would apply to a similar project undertaken on its own behalf. With respect to each XOMA
Library Project, AFFIMED shall not discriminate against the XOMA Library Project in favor of any Third Party or any of AFFIMED’s internal projects with respect to the application of any techniques or know-how or access to technology or skilled
personnel. For each calendar quarter while a XOMA Library Project is being conducted, AFFIMED, with the consultation and approval of XOMA, shall, as necessary, update and revise the cost estimates and timelines associated therewith. AFFIMED shall
represent and warrant that its activities, the materials and methods used by AFFIMED and any Project Materials provided to XOMA shall be free of claims of patent infringement or misappropriation by any Third Party. 

  
 -19- 

 5.2. Cost Reimbursement. For each XOMA Library Project that meets their applicable XOMA
Library Specification, XOMA will reimburse AFFIMED for all Direct AFFIMED Costs actually incurred by AFFIMED; provided, however, that XOMA shall not be obligated to pay any Direct AFFIMED Cost that exceeds ***** of the estimate of costs
approved by XOMA in accordance with Section 5.l(b). For the first XOMA library Project that meets the applicable XOMA Library Specification, XOMA shall bear ***** of the Direct AFFIMED Costs. Payments are due ***** from receipt of each
invoice. Late payments shall accrue interest from the date such amount(s) were due at the prime rate reported by the Bank of America plus *****, or the greatest, amount allowed by law, whichever is less. AFFIMED shall create and maintain sufficient
records to provide backup for any amount reimbursed by XOMA. In the event a XOMA Library Project does not meet the applicable XOMA Library Specification such XOMA Library Project shall not be counted against the maximum of ***** XOMA Library
Projects provided for under Section 5.1 and XOMA and AFFIMED shall discuss in good faith the best method of correcting any failure to meet the XOMA Library Specification. 

5.3. Transfer of Project Materials. Within ***** after a written request by XOMA, AFFIMED shall, pursuant to XOMA’s form of sale
document, sell for the sum of ***** to XOMA all of the Project Materials, including the XOMA Library, arising out the applicable XOMA Library Project. AFFIMED shall provide up to ***** of AFFIMED scientific staff time at AFFIMED facilities during
the first ***** after transfer to XOMA (which period may be extended by mutual consent of the parties, which consent shall not be unreasonably withheld) *****. For the avoidance of doubt, other than the payment of the applicable Direct AFFIMED costs
and the *****, XOMA shall owe no further financial obligations to AFFIMED for any use of the XOMA Library, including, without limitation, making, having made, using, selling, offering to sell, importing or exporting any Immunoglobulin derived
therefrom. AFFIMED represents and warrants that the Project Materials to be transferred pursuant to this Section 5.3 will comprise those materials reasonably necessary for reasonably qualified Third Parties to conduct antibody discovery
activities. 
 5.4. XOMA Rights/Grant of License to XOMA. 

(a) With the exception of the AFFIMED Technology (other than as required to make, use, sell, offer for sale, import or export Project
Materials) and subject to the provisions of Section 5.4(c), all information, know-how, inventions, compositions of matter or articles of manufacture, including without limitation customized protein, Immunoglobulin or nucleic acid libraries,
expression vectors, ideas, inventions, concepts, discoveries, data, designs, formulas, specifications, procedures for experiments and tests and other protocols, results of experimentation and testing, techniques and assay protocols arising out of or
directly relating to a XOMA Library Project (the “Project Materials”) and any intellectual property rights arising therefrom shall be owned solely and exclusively by XOMA. 

  
 -20- 

 (b) Subject to the mandatory provisions of the German Act on Employee’s Inventions
(“Arbeitnehmererfindungsgesetz”), as amended, AFFIMED shall give XOMA reasonable written notice of any Inventions made by an AFFIMED employee during any activities undertaken on behalf of XOMA pursuant to this Agreement. AFFIMED,
with the consultation and at the direction of XOMA, shall record, disclose and file patent applications for any inventions arising out of or relating to any activities undertaken on behalf of XOMA under this Agreement or any Project Materials and
shall immediately, and without further consideration, execute and cause the inventors thereof to execute such agreements as to effectively and permanently assign such patent applications and any patents issuing therefrom to XOMA. In addition,
AFFIMED shall, at its own cost and expense, execute such documents as may be reasonably necessary to assign all right, title and interest in and to such Project Materials and any intellectual property rights arising therefrom or from a XOMA Library
Project, including from any Inventions subject to the Arbeitnehmererfindungsgesetz. AFFIMED shall, at XOMA’s sole expense and discretion, cooperate with XOMA in the filing, prosecution, maintenance, defense or enforcement of any right or
interest arising out of or relating to the Project Materials and any intellectual property rights arising therefrom or from a XOMA Library Project. AFFIMED shall establish internal procedures to insure that access to Project Materials is safeguarded
from Third Parties or any AFFIMED employee not directly working on the XOMA Library Project. At XOMA’s option, AFFIMED will execute such documents and assignments as are necessary to evidence XOMA’s right, license and exclusive ownership
interest in and to the subject matter of each XOMA Library Project or Project Materials; 
 (c) To the maximum extent permissible as
it relates to any XOMA Library and any Project Materials relating thereto and with the exception of the AFFIMED Technology (other than as required to make, use, sell, offer for sale, import or export Project Materials), AFFIMED shall grant,
sublicense or extend the benefit to XOMA of any rights, licenses or other rights to any intellectual property, including patents or patent rights, under the control of AFFIMED or as to which AFFIMED has the power to make such grant, provided,
however, that in the event such grant, sublicense or extension of benefit requires the payments of any amount by XOMA or AFFIMED, at XOMA’s option, XOMA may either pay and hold AFFIMED harmless from such payments or waive such grant. The
license grant of this Section 5.4(c) excludes (i) the conduct of a Commercial Antibody Phage Display Business or a Commercial Evolution Business, and (ii) the conduct of any phage display services or other Immunoglobulin discovery
activities for any Third Party except a XOMA Licensee. 
 5.5. Covenant Not To Sue. AFFIMED covenants that it shall not assert
any claims or permit any Third Party over whom it has control to initiate or assist in any way in the initiation or prosecution of any action asserting a claim of infringement under the AFFIMED Patent Rights against XOMA or any XOMA Licensee or
misappropriation of the Project Materials against XOMA to the extent such claims arise out of (a) use of the Project Materials by XOMA as permitted under the provisions of this Agreement or (b) the discovery, isolation, optimization or
development by XOMA or a XOMA Licensee, or the manufacture, use, offer for use, sale, offer for sale, importation and exportation, of any Immunoglobulin or product containing or comprising an Immunoglobulin which was discovered under conditions
which but for this license would constitute misappropriation of any AFFIMED Technology or infringement of the AFFIMED Patent Rights. 

  
 -21- 

 5.6. Ownership; Enforcement. AFFIMED retains ownership and control of the AFFIMED Patent
Rights and the AFFIMED Technology; provided that any transfer of the AFFIMED Patent Rights or the AFFIMED Technology shall be subject to the license and other rights granted XOMA hereunder. AFFIMED may use and commercialize the AFFIMED Patent
Rights and the AFFIMED Technology itself or with any Third Party. AFFIMED retains the right, at its sole discretion, to enforce, maintain and otherwise protect the AFFIMED Patent Rights and the AFFIMED Technology. 

ARTICLE 6 
 XOMA PROCESS
DEVELOPMENT PROJECT 
 6.1. XOMA Process Development Activities. 

(a) Pursuant to the terms of this Agreement and the Work Plan(s), XOMA shall provide to AFFIMED cell line development and process development
services (the “Services”) directed to the creation of an E. Coli cell line for one (1) AFFIMED Product created by and under the exclusive control of AFFIMED. 

(b) Work Plan Development Process. Annexed hereto as Schedule 6.1(b) is a detailed work plan (the “Work Plan”)
for the schedule of activities to be undertaken with respect to the AFFIMED Product subject to this Article 6. Upon mutual consent, the Work Plan may be reviewed and modified by AFFIMED AND XOMA. The Work Plan sets forth the Services to be performed
by XOMA, the anticipated timing, work flow and deliverables for the process development and cell line development activities to be undertaken with respect to such AFFIMED Product and the expected attributes of any deliverables (the
“Deliverables”) to be provided by XOMA to AFFIMED. The Work Plan shall be implemented by a working committee comprised of not less than two (2) XOMA employees and two (2) AFFIMED employees to oversee and review the
implementation of the Work Plan. 
 (c) Discharge of Work Plan. XOMA shall use its commercially reasonable efforts to perform the
Services and to provide the facility, supplies and staff necessary to complete the Work Plan, as it may be modified as provided herein, in accordance with the terms of this Agreement at XOMA’s fully burdened cost. In the event of any conflict
between the terms set forth in this Agreement and the terms set forth in the Work Plan, the terms contained in this Agreement shall govern. With respect to the Services to be performed: 

 

	 	(i)	AFFIMED will provide XOMA with sufficient amounts of cell line reference standards or other materials as required to perform the Services, as well as all documentation and such other data owned or controlled by AFFIMED,
XOMA, in its sole judgment) determines may be necessary to apprise XOMA of the stability of the materials, process characteristics, proper storage, and manufacturing and safety requirements; 

  
 -22- 

	 	(ii)	XOMA reserves the right to employ subcontractors from time-to-time to undertake certain activities related to the provision of Services or the Work Plan. All subcontractors will be subject to obligations of
confidentiality consistent with provisions of this Agreement. XOMA will be responsible for the performance of any subcontractor used by it; and 

  

	 	(iii)	in discharging its obligations under the Work Plan, XOMA shall comply with applicable government regulatory requirements appropriate to the provision of Services and such Work Plan. Should any applicable government
regulatory requirements be changed, XOMA will use commercially reasonable efforts to comply with the applicable changed requirements. If compliance with such applicable changed regulatory requirements necessitates, in the reasonable judgment of
XOMA, a material change in the Services or Work Plan, or an increase in the costs of the Services provided by XOMA, XOMA will submit to AFFIMED a revised technical and cost proposal for AFFIMED’s acceptance and, on and after the date of such
submission, upon written notice to AFFIMED, may suspend any and all Services impacted by the applicable changed regulatory requirements until such time as AFFIMED and XOMA reach agreement on a revised proposal. 

6.2. XOMA Milestone. Upon achievement of the Milestone (as that term is defined in the Work Plan), AFFIMED will pay to XOMA, by wire
transfer, the sum of *****. This amount shall be creditable by AFFIMED against any other payments due to XOMA pursuant to Article 3 hereunder. 

6.3. Intellectual Property Matters. AFFIMED shall own all right, title and interest in and to any and all Deliverables and any
inventions relating specifically to the AFFIMED Product subject to the Work Plan, and any AFFIMED know-how relating thereto. XOMA shall own and retain all rights to any inventions relating to manufacturing methods and processes including any
production, purification and development of the bacterial cell line. 
 ARTICLE 7 

CONFIDENTIALITY 
 7.1.
Confidential Information. Except as expressly provided herein, the parties agree that, for the term of this Agreement and for ***** thereafter, the receiving party shall keep completely confidential and shall not publish or otherwise disclose
and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing party hereto, except to the extent that it can be established by the receiving party by written
proof that such Confidential Information: 
  

	 	(a)	was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 

  
 -23- 

	 	(b)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; 

  

	 	(c)	became generally available to the public or otherwise part of the public domain after its disclosure other than through any act or omission of the receiving party in breach of this Agreement; or 

 

	 	(d)	was subsequently lawfully disclosed to the receiving party by a person other than a party hereto. 

7.2. Permitted Use and Disclosures. Each party hereto may use or disclose information disclosed to it by the other party to the extent
such use or disclosure is reasonably necessary in complying with applicable law or government regulations or conducting clinical trials; provided, however, that if a party is required to make any such disclosure of another party’s
Confidential Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the latter party of such disclosure and, will use its reasonable efforts to secure confidential treatment of such information
prior to its disclosure (whether through protective orders or otherwise). Attached hereto as Schedule 7.2 is a redacted copy of this Agreement which AFFIMED shall be free, without obtaining any consent from XOMA, to provide to Third Parties
who indicate an interest in becoming an AFFIMED Collaborator. 
 7.3. Confidential Terms. Except as expressly provided herein, each
party agrees not to disclose any terms of this Agreement to any Third Party without the consent of the other party; provided, that disclosures may be made as required by securities or other applicable laws, or to a party’s accountants,
attorneys and other professional advisors. 
 7.4. Agreement Announcement. The parties hereby agree to the release of a press release
in the form attached hereto as Schedule 7.4 upon full execution of this Agreement and that the fact of the consummation of this Agreement shall be deemed to be in the public domain. 

ARTICLE 8 
 ARTICLES
REPRESENTATIONS AND WARRANTIES 
 8.1. Representations and Warranties. 

(a) XOMA represents and warrants to AFFIMED that: (i) it is the sole and exclusive owner or exclusive licensee of all right, title and
interest in the XOMA Patent Rights; (ii) XOMA has the legal right, authority and power to enter into this Agreement; 

  
 -24- 

 
(iii) this Agreement shall constitute a valid and binding obligation of XOMA enforceable in accordance with its terms; and (iv) the performance of obligations under this Agreement by XOMA
shall not result in a breach of any agreements, contracts or other arrangements to which it is a party. 
 (b) AFFIMED represents and
warrants to XOMA that: (i) it is the sole and exclusive owner or exclusive licensee of all right, title and interest in the AFFIMED Patent Rights; (ii) AFFIMED has the legal right, authority and power to enter into this Agreement;
(iii) this Agreement shall constitute a valid and binding obligation of AFFIMED enforceable in accordance with its terms; (iv) the performance of obligations under this Agreement by AFFIMED shall not result in a breach of any agreements,
contracts or other arrangements to which it is a party and (v) the AFFIMED Patent Rights are all of the patents or patent applications under its control or as to which it can grant licenses or sublicense that cover or related to Antibody Phage
Display or the activity of XOMA business as disclosed to it by XOMA; and (vi) each of the AFFIMED Third Party Licenses is in full force and effect and, to AFFIMED’s knowledge, is enforceable in accordance with its terms and there exists no
breach of any thereof. 
 8.2. Disclaimer. Nothing in this Agreement is or shall be construed as: 

 

	 	(a)	A warranty or representation by XOMA or AFFIMED as to the validity or scope of any claim or patent within the XOMA Patent Rights or the AFFIMED Patent Rights, as the case may be; 

 

	 	(b)	A warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of any patent rights or other intellectual property
right of any Third Party; 

  

	 	(c)	An obligation to bring or prosecute actions or suits against Third Parties for infringement of any of the XOMA Patent Rights or the AFFIMED Patent Rights; 

 

	 	(d)	An obligation to maintain any patent or to continue to prosecute any patent application included within the XOMA Patent Rights or the AFFIMED Patent Rights in any country; or 

 

	 	(e)	Granting by implication, estoppel, or otherwise any licenses or rights under patents or other rights of XOMA, AFFIMED or Third Parties, regardless of whether such patents or other rights are dominant or subordinate to
any patent within the XOMA Patent Rights or the AFFIMED Patent Rights, as the case may be. 

 8.3. No Other Warranties.
EXCEPT AS OTHERWISE SET FORTH IN SECTION 8.1 ABOVE, NEITHER PARTY HERETO MAKES ANY WARRANTIES WITH RESPECT TO ANY OF THE PATENT RIGHTS, MATERIALS OR KNOW-HOW LICENSED HEREUNDER, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE
OR OTHERWISE, AND EACH PARTY 

  
 -25- 

 
SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, OF FITNESS FOR A PARTICULAR PURPOSE, OF VALIDITY OF SUCH PATENT RIGHTS, MATERIALS OR KNOW-HOW, OR OF NON-INFRINGEMENT OF
THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY. 
 ARTICLE 9 

TERM AND TERMINATION 

9.1. Term. Subject to Sections 9.4 and 9.5 hereof, the term of this Agreement will commence on the Effective Date and
(a) with regard to the license and other rights granted to AFFIMED and any AFFIMED Collaborators by XOMA pursuant to Article 2, this Agreement shall remain in full force and effect until the last to expire of the XOMA Patent Rights or the tenth
anniversary of the First Commercial Sale of the last Immunoglobulin subject to Section 2.5(b) to be launched, whichever is later, unless earlier terminated by XOMA pursuant to Section 9.2 or 9.3; and (b) with regard to the license and
other rights granted to XOMA and any XOMA Development Partners or XOMA Licensees by AFFIMED pursuant to Article 4, this Agreement shall remain in full force and effect until the last to expire of the AFFIMED Patent Rights; provided, however,
that upon such expiration and absent any earlier termination pursuant to Section 9.2 or 9.3, XOMA shall have a royalty-free, fully paid up right and license to continue to use the Project Materials as permitted by Article 4. 

9.2. Termination for Material Breach. With regard to (a) the license and other rights granted to AFFIMED and any AFFIMED
Collaborators by XOMA pursuant to Article 2, or (b) the license and other rights granted to XOMA and any XOMA Development Partners or XOMA Licensees by AFFIMED pursuant to Article 4, this Agreement may be terminated by the non-breaching party
upon any material breach by XOMA or AFFIMED, as the case may be, of any material obligation or condition of the Agreement, in either case effective ***** after giving notice to the breaching party of such termination in the case of a payment breach
and ***** after giving written notice to the breaching party of such termination in the case of any other breach, which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such breach is cured or shown to be
non-existent within the aforesaid ***** or ***** period, the notice shall be deemed automatically withdrawn and of no effect and the notifying party shall provide written notice to the breaching party of the withdrawal. A termination of the
breaching party’s rights and licenses pursuant to this Section 9.2 shall not effect the non-breaching party’s rights and licenses, which shall continue until otherwise terminated in accordance with this Agreement. 

9.3. Termination for Insolvency. If voluntary or involuntary proceedings by or against either party are instituted in bankruptcy under
any insolvency law, or a receiver or custodian is appointed for either party, or proceedings are instituted by or against either party for corporate reorganization or the dissolution of such party, which proceedings, if involuntary, shall not have
been dismissed within ***** after the date of filing, or if either party makes an assignment for the benefit of creditors, or substantially all of 

  
 -26- 

 
the assets of either party are seized or attached and not released within ***** thereafter, the other party may immediately terminate this Agreement effective upon notice of such termination.

 9.4. Effect of Termination. 

(a) Termination of this Agreement shall not release any party hereto from any liability which, at the time of such termination, has already
accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. It
is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the non-breaching party may be entitled to injunctive relief as a remedy for any such breach. Such remedy shall not be deemed to
be the exclusive remedy for any such breach of this Agreement, but shall be in addition to all other remedies available at law or in equity. 

(b) Upon any termination of this Agreement, AFFIMED and XOMA shall promptly return to the other party all Confidential Information received
from the other party (except that each party may retain one copy for its files solely for the purpose of determining its: rights and obligations hereunder). 

(c) Except as expressly provided in this Article 9, all licenses granted under Article 2 hereof shall terminate and be of no further effect
upon the termination of this Agreement. 
 (d) For the avoidance of doubt, any termination of this Agreement shall not effect any right or
license to XOMA, any XOMA Development Partner, any XOMA Licensee or any Third Party covered by Article 4 may have with respect to any Project Materials, Immunoglobulins, compositions of matter or articles of manufacture existing as of the effective
date of the termination (the “Existing Materials”) and as to such Existing Materials, the grants of Article 4 shall continue until the last to expire of the applicable AFFIMED Patent Rights. 

9.5. Survival. Sections 2.8, 2.9, 2.10, 3.1 through 3.5, 5.4(a), 5.4(b), 9.1, 9.2, 9.4 and 9.5, and Articles 1, 4 (to the extent
provided in Section 9.2), 7, 8 and 10, of this Agreement shall survive any termination hereof. 
 ARTICLE 10 

MISCELLANEOUS PROVISIONS 
 10.1.
Governing Laws. This Agreement and any dispute, including without limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of New York,
without reference to conflicts of laws principles. 
 10.2. Assignment. Neither party may transfer or assign this Agreement, directly
or indirectly, or any of its rights hereunder without the prior written consent of the other 

  
 -27- 

 
party, other than (a) to one or more Affiliates, (b) to a successor of XOMA Ltd. under a Change in Control of XOMA Ltd., or (c) in the case of XOMA, to a Third Party in connection
with the transfer or sale of all or substantially all of its business relating to Immunoglobulins. Any such attempted transfer or assignment in violation of this Section 10.2 shall be void; provided that in the, event of a permitted
Change in Control, the original party’s (or its successor’s) obligations hereunder shall continue. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 

10.3. Certain Changes in Control. (a) Notwithstanding any other provision of this Agreement to the contrary, solely at XOMA’s
option, unless the provisions of Section 10.3(b) are met, the license and other rights granted to AFFIMED and any AFFIMED Collaborators pursuant to Article 2 shall automatically terminate, in whole or in part, without further action by the
parties, in the event of a transaction or series of related transactions in which AFFIMED is a party and which results in a Change in Control of AFFIMED or the sale of all or substantially all of the antibody discovery or assets used for Antibody
Phage by AFFIMED. 
 (b) The provisions of Section 10.3(a) shall, for a single Change of Control transaction not apply to the
purchase of AFFIMED or all of the antibody discovery assets used for Antibody Phage Display by AFFIMED to a Third Party if (i) the acquiring Third Party has a market capitalization of less than ***** (as determined either by the acquirer’s
share price on the relevant stock exchange thirty (30) days prior to the Change of Control becoming effective or (when the acquiring Third Party is not listed) by the value as determined in the acquirer’s last financing round according to
the generally accepted principles for the evaluation of companies as applied in such a financing round, provided, however, that the market capitalization threshold set forth in this Section 10.3(b)(i) shall be adjusted (i.e., increased
or decreased) by multiplying it by a fraction (expressed as a percentage), the numerator of which is the average NASDAQ Composite Index for the thirty (30) days beginning sixty (60) days, and ending thirty (30) days, prior to the
Change of Control becoming effective and the denominator of which is the average NASDAQ Composite Index for the thirty (30) days after the Effective Date; (ii) such acquiring Third Party either is not engaged in a Commercial Antibody Phage
Display Business or Commercial Antibody Evolution Business or is engaged in a Commercial Antibody Phage Display Business or Commercial Antibody Evolution Business that has been licensed by XOMA (in which case XOMA shall elect which license
continues); (iii) such acquiring Third Party quitclaims any right to extend this Agreement to any Immunoglobulin discovered, isolated, characterized or optimized by its or any other Third Party prior to the effective date of the Change of
Control; and (iv) such acquiring Third Party agrees to be bound by all the applicable provisions of this Agreement on a going forward basis. 

10.4. Waiver. No waiver of any rights shall be effective unless consented to in writing by the party to be charged and the waiver of
any breach or default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 

  
 -28- 

 10.5. Severability. In the event that any provisions of this Agreement are determined to
be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision. 

10.6. Notices. All notices, requests and other communications hereunder shall be in writing and shall be delivered or sent in each case
to the respective address specified below, or such other address as may be specified in writing to the other party hereto, and shall be effective on receipt: 
  

			
	AFFIMED:	  	 Affimed Therapeutics AG
 Technologiepark

Im Neuenheimer Feld 582
 69120 Heidelberg

Germany
 Attn: Chief Executive Officer

		
	XOMA:	  	 XOMA Ireland Limited
 Shannon Airport House

Shannon, County Clare
 Ireland

Attn: Company Secretary

	
	with a copy (which shall not constitute notice) to:
		
		  	 Cahill Gordon & Reindel LLP 

80 Pine Street
 New York, NY 10005

U.S.A.
 Attn: Geoffrey E. Liebmann

 10.7. Independent Contractors. Both parties are independent contractors under this Agreement. Nothing
contained in this Agreement is intended nor is to be construed so as to constitute XOMA or AFFIMED as partners or joint venturers with respect to this Agreement. Except as expressly provided herein, neither party shall have any express or implied
right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any third party. 

10.8. Compliance with Laws. In exercising their rights under this license, the parties shall comply in all material respects with the
requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement. 

10.9. Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by one party to the other are, for all purposes
of Section 365(n) of Title XI of the United States Code (“Title XI”), licenses of rights to “intellectual property” as defined in Title XI. During the term of this Agreement each party shall create and

  
 -29- 

 
maintain current copies to the extent practicable of all such intellectual property. If a bankruptcy proceeding is commenced by or against one party under Title XI, the other party shall be
entitled to a copy of any and all such intellectual property and all embodiments of such intellectual property, and the same, if not in the possession of such other party, shall be promptly delivered to it (a) upon such party’s written
request following the commencement of such bankruptcy proceeding, unless the party subject to such bankruptcy proceeding, or its trustee or receiver, elects within thirty (30) days to continue to perform all of its obligations under this
Agreement, or (b) if not delivered as provided under clause (a) above, upon such other party’s request following the rejection of this Agreement by or on behalf of the party subject to such bankruptcy proceeding. If a party has taken
possession of all applicable embodiments of the intellectual property of the other party pursuant to this section 10.9 and the trustee in bankruptcy of the other party does not reject this Agreement, the party in possession of such intellectual
property shall return such embodiments upon request. If a party seeks or involuntarily is placed under Title XI and the trustee rejects this Agreement as contemplated under 11 U.S.C. 365(n)(l), the other party hereby elects, pursuant to
Section 365(n) of Title XI, to retain all rights granted to it under this Agreement to the extent permitted by law. 
 10.10. Use of
Name. Neither party shall use the name or trademarks of the other party, except to the extent that a party is permitted to use the Confidential Information of the other party pursuant to Article 7, without the prior written consent of such other
party. 
 10.11. Further Actions. Each party agrees to execute, acknowledge and deliver such further instruments, and do such other
acts, as may be necessary and appropriate in order to carry out the purposes and intent of this Agreement. 
 10.12. Entire Agreement;
Amendment. This Agreement constitutes the entire and exclusive Agreement between the parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect thereof.
No amendment or addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the parties. 

10.13. Arbitration. 
 (a)
Any controversy or claim between the parties to this Agreement (other than any dispute which arises out of or relates to infringement, validity and/or enforceability of the XOMA Patent Rights or the AFFIMED Patent Rights) arising out of or relating
to this Agreement or the breach thereof shall be finally determined by arbitration in New York, in accordance with the International Arbitration Rules of the International Centre for Dispute Resolution (“ICDR”) or other rules agreed
to by the parties involved in the dispute, by a panel of three neutral arbitrators (at least two of whom who shall have significant experience in the biotechnology industry), who shall be selected by the parties involved in the dispute using the
procedures for arbitrator selection of the ICDR. 

  
 -30- 

 (b) The parties acknowledge that this Agreement evidences a transaction involving interstate
commerce and is subject to the New York Convention on enforcement of arbitral awards. Insofar as it applies, the United States Arbitration Act shall govern the interpretation of, enforcement of, and proceedings pursuant to the arbitration clause in
this Agreement. Except insofar as the United States Arbitration Act applies to such matters, the agreement to arbitrate set forth in this Section 10.13 shall be construed, and the legal relations among the parties shall be determined in
accordance with, the substantive laws of the State of New York. 
 (c) The panel shall render its decision and award, including a statement
of reasons upon which such award is based, within thirty (30) days after the arbitration hearing. The decision of the panel shall be determined by majority vote among the arbitrators, shall be in writing and shall be binding upon the parties
involved in the dispute, final and non-appealable. Judgment upon the award rendered by the panel may be entered in any court having jurisdiction thereof. 

(d) Except as provided under the United States Arbitration Act and with respect to the infringement, validity and/or enforceability of the
XOMA Patent Rights or the AFFIMED Patent Rights, no action at law or in equity based upon any dispute that is subject to arbitration under this Section 10.13 shall be instituted. 

(e) The arbitral panel shall have the authority to award, in its discretion, part or all the expenses of any arbitration pursuant to this
Section 10.13, including fees and expenses of the prevailing party’s attorneys, fees and expenses of the arbitrators, and fees and expenses of any witness or the cost of any proof produced at the request of the arbitrators, to the
prevailing party. 
 10.14. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. 

  
 -31- 

 IN WITNESS WHEREOF, XOMA and AFFIMED have executed this Agreement in duplicate originals by duly
authorized officers. 
  

									
	AFFIMED THERAPEUTICS AG	 		 	XOMA IRELAND LIMITED
					
	By:	 	 /s/ Melvyn Little
	 		 	By:	 	 /s/ Alan Kane

		 	Name: Melvyn Little, Ph.D	 		 	Alan Kane, Director
		 	Title:   Chief Scientific Officer	 		 		 	duly authorized for and on behalf of XOMA Ireland Limited in the presence of:
					
		 		 		 		 	 /s/

  
 -32- 

 SCHEDULE 1.4 

AFFIMED Antibody Patents 
  

					
	 	  	 PREPARATION AND USE

OF GENE BANKS OF
 HUMAN
ANTIBODIES
	  	 PREPARATION AND USE

OF GENE BANKS OF
 SYNTHETIC HUMAN

ANTIBODIES

	PUBLISHED PCT	  	-?No PCT?	  	WO-A-88/06630
	US	  	 US-B 6,319,690 GRANTED
 Nov. 20, 2001
	  	 US-B 5,840,479 GRANTED
 Nov. 24
1998

	EUROPE	  	 EP-A 0 440 147
 EP-A 1566442
	  	 EP-B 0 440 146 GRANTED
 Nov 20
1996

	AUSTRALIA	  	 AU 633682, AU 7011391
 PENDING
	  	 AU638535, AU7011591
 PENDING

	JAPAN	  	 JP-AA 4211394 PENDING
 JP 03514778 B2
	  	JP-AA 4211395 PENDING
	CANADA	  	CA-A 2035381 PENDING	  	CA-A 2035384 PENDING
	SOUTH KOREA	  	KR 18623 B1	  	KR 221897B1
	PORTUGAL	  	PT-B 96625	  	PT-B 96624
	GERMANY	  	 DE-A 40 03 881,
 DE-A 40 02 898 PRIORITY
APPLICATIONS, PENDING
 DE 59109264
	  	 DE-A 40 03 880,
 DE-A 40 02 897 PRIORITY
APPLICATIONS, PENDING
 DE 59108350

	AUSTRIA	  	AT-E 0277179	  	AT-E 145427 PENDING
	ISRAEL	  	IE 910335	  	IE 910336
	SPAIN	  	ES 2225816	  	ES 2097157
	GREECE	  		  	GR 3022131
	DENMARK	  		  	DK 044016

									
	 	  	 Phagemid for Anti-body
Screening

(M. Little)
	  	 Recombinant

Antibodies at
 the Surface of

 E. Coli (M.

Little)
	  	 Dimeric and

Multimeric
 Antigen Binding

Structure
 (Affimed)
	  	 Single-Strand

Antigen Binding
 Structure

(M. Little)

	US	  	 US 5,849,500
 US 5,985,588

US 6,127,132
 US 6,387,627

US 6, 730,483
 US 20020160463A1
	  		  	2005/0079170 PENDING	  	
					
	PCT	  	W09308288	  		  		  	
	EUROPE	  	 EP1065271A1
 EP0547201B1
	  	WO 93/01287	  	 WO 03/025018
 EP 1293514
	  	WO 02/50118
	GERMANY	  	 DE59209896CO
 DE4122599C2

DE4122599A 1
	  		  		  	
	JAPAN	  	JP06500930T2	  		  		  	
	SPAIN	  		  	ES2118822T3	  		  	
	AUSTRALIA	  		  		  		  	AU0234488A5

  
 -2- 

 SCHEDULE 1.7 

AFFIMED Third Party Licenses 

Affimed has license agreements with Dade-Behring, CAT and Dyax. 
  

	l.	Dade-Behring: 

 Affimed has an exclusive license from Dade-Behring for the generation of human IgM and synthetic
antibody libraries. 
  

	2.	CAT 

 Affimed has a sublicense from CAT for the generation of antibody libraries and screening by phage display.

  

	3.	Dyax 

 Affimed has a royalty free cross-licensing agreement for the use of their phage display technology. In
return, Dyax has the right to use our IgM library IP for the generation of IgM-based libraries. The rights to make or use such a library cannot be transferred to a third party. 

 SCHEDULE 1.34 

XOMA Patent Rights –Bacterial Expression 

A. Title: Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use 

Inventors:        Robinson, Liu, Horwitz, Wall, Better 

 

	1)	Based on PCT/US86/02269, which is a continuation-in-part of U.S. Application No. 06/793,980 filed November 1, 1985 (abandoned). 

 

					
	 COUNTRY
	  	 APPLICATION NO.
	  	 PATENT NO.

	Australia	  	65981/86	  	606,320
	Denmark	  	3385/87	  	PR 175680 B1
	Taiwan	  	75105650	  	51922
	*United States	  	06/793,980	  	
	*United States	  	U.S. National Phase of PCT/US86/02269	  	

  

	*	Cases abandoned in favor of a continuing application. 

  

	2)	Based on PCT/US88/02514, which corresponds to U.S. Application No. 07/077,528, which is a continuation-in-part PCT/US86/02269 (abandoned), which is a continuation-in-part of U.S. Application No. 06/793,980
(abandoned). 

  

					
	 COUNTRY
	  	 APPLICATION NO.
	  	 PATENT NO.

	Australia	  	23244/88	  	632,462
	Canada	  	572,398	  	1,341,235
	Denmark	  	192/90	  	174824
	Denmark	  	200301155	  	PR 175654 B1
	Denmark	  	200301156	  	PR 175581 B1
	Europe	  	EP 88907510.7	  	EP 0371998
	 Austria
	  	EP 88907510.7	  	EP 0371998
	 Belgium
	  	EP 88907510.7	  	EP 0371998
	 France
	  	EP 88907510.7	  	EP 0371998
	 Germany
	  	BP 88907510.7	  	p 3888186.1
	 Italy
	  	EP 88907510.7	  	EP 0371998
	 Luxembourg
	  	EP 88907510.7	  	EP 0371998
	 Netherlands
	  	EP 88907510.7	  	EP 0371998
	 Sweden
	  	EP 88907510.7	  	EP 0371998
	 Switzerland/Liechtenstein
	  	EP 88907510.7	  	EP 0371998
	 United Kingdom
	  	EP 88907510.7	  	EP 0371998
	Europe	  	EP 93100041.8	  	EP 0550400
	 Austria
	  	EP 93100041.8	  	EP 0550400
	 Belgium
	  	EP 93100041.8	  	EP 0550400

					
	 COUNTRY
	  	 APPLICATION NO.
	  	 PATENT NO.

	 France
	  	EP 93100041.8	  	EP 0550400
	 Germany
	  	EP 93100041.8	  	p 3855421.6
	 Italy
	  	EP 93100041.8	  	EP 0550400
	 Luxembourg
	  	EP 93100041.8	  	EP 0550400
	 Netherlands
	  	EP 93100041.8	  	EP 0550400
	 Sweden
	  	EP 93100041.8	  	EP 0550400
	 Switzerland/Liechtenstein
	  	EP 93100041.8	  	EP 0550400
	 United Kingdom
	  	EP 93100041.8	  	EP 0550400
	Europe	  	EP 95119798.7	  	EP 0731167
	 Austria
	  	EP 95119798.7	  	EP 0731167
	 Belgium
	  	EP 95119798.7	  	EP 0731167
	 France
	  	EP 95119798.7	  	EP 0731167
	 Germany
	  	EP 95119798.7	  	p 3856440.12
	 Italy
	  	EP 95119798.7	  	EP 0731167
	 Luxembourg
	  	EP 95119798.7	  	EP 0731167
	 Netherlands
	  	EP 95119798.7	  	EP 0731167
	 Sweden
	  	EP 95119798.7	  	EP 0731167
	 Switzerland/Liechtenstein
	  	EP 95119798.7	  	EP 0731167
	 United Kingdom
	  	EP 95119798.7	  	EP 0731167
	Japan	  	506481/88	  	2991720
	*United States	  	07/077,528	  	

  

	*	Cases abandoned in favor of a continuing application. 

  

	3)	Based on U.S. Application No. 07/501,092 filed March 29, 1990, which is a continuation-in-part of U.S. Application No. 07/077,528 (Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use;
Robinson, Liu, Horwitz, Wall, Better) and of U.S. Application No. 07/142,039 (Novel Plasmid Vector with Pectate Lyase Signal Sequence; Lei, Wilcox) . 

  

					
	 COUNTRY
	  	 APPLICATION NO.
	  	 PATENT NO.

	 *United States
	  	07/501,092	  	
	*United States	  	07/987,555	  	
	*United States	  	07/870,404	  	
	*United States	  	08/020,671	  	
	*United States	  	09/722,425	  	Abandoned
	*United States	  	091722,315	  	Abandoned
	United States	  	08/235,225	  	5,618,920
	United States	  	08/299,085	  	5,595,898
	United States	  	08/472,691	  	6,204,023
	United States	  	08/467,140	  	5,698,435
	United States	  	08/450,731	  	5,693,493
	United States	  	08/466,203	  	5,698,417
	United States	  	10/040,945	  	Pending

  

	*	Cases abandoned in favor of a continuing application. 

  
 -2- 

 B. Title: Novel Plasmid Vector with Pectate Lyase Signal Sequence 

Inventors: Lei, Wilcox 
 Based on U.S. Application
No. 07/142,039 filed January 11, 1988 and PCT/US89/00077. 
  

					
	 COUNTRY
	  	 APPLICATION NO.
	  	 PATENT NO.

	 Australia
	  	29377/89	  	/627443
	 Canada
	  	587,885	  	1,338,807
	 Europe
	  	EP 89901763.6	  	EP 0396612
	 Austria
	  	EP 89901763.6	  	EP 0396612
	 Belgium
	  	EP 89901763.6	  	EP 0396612
	 France
	  	EP 89901763.6	  	EP 0396612
	 Germany
	  	EP 89901763.6	  	689 26 882 T2
	 Italy
	  	EP 89901763.6	  	EP 0396612
	 Luxembourg
	  	EP 89901763.6	  	EP 0396612
	 Netherlands
	  	EP 89901763.6	  	EP 0396612
	 Sweden
	  	EP 89901763.6	  	EP 0396612
	 Switzerland/Liechtenstein
	  	EP 89901763.6	  	EP 0396612
	 United Kingdom
	  	EP 89901763.6	  	EP 0396612
	 Japan
	  	501661/89	  	2980626
	 *United States
	  	07/142,039	  	
	 United States
	  	08/472,696	  	5,846,818
	 United States
	  	08/357,234	  	5,576,195

  

	*	Cases abandoned in favor of a continuing application. 

 C. Title: AraB Promoters and Method of
Producing Polypeptides, Including Cecropins, by Microbiological Techniques 
 Inventors: Lai, Lee, Lin, Ray, Wilcox 

Based on PCT/US86/00131, which is a continuation-in-part of U.S. Application No. 06/695,309 

filed January 28, 1985 (abandoned). 
  

					
	 COUNTRY
	  	 APPLICATION NO.
	  	 PATENT NO.

	Europe	  	EP 86900983.7	  	EP 0211047
	 Austria
	  	EP 86900983.7	  	EP 0211047
	 Belgium
	  	EP 86900983.7	  	EP 0211047
	 France
	  	EP 86900983.7	  	EP 0211047

  
 -3- 

					
	 COUNTRY
	  	 APPLICATION NO.
	  	 PATENT NO.

	Germany	  	EP 86900983.7	  	P3689598.9-08
	Italy	  	EP 86900983.7	  	EP 0211047
	Luxembourg	  	EP 86900983.7	  	EP 0211047
	Netherlands	  	EP 86900983.7	  	EP 0211047
	Sweden	  	EP 86900983.7	  	EP 0211047
	Switzerland/Liechtenstein	  	EP 86900983.7	  	EP 0211047
	United Kingdom	  	EP 86900983.7	  	EP 0211047
	Finland	  	863891	  	94774
	Japan	  	500818/86	  	2095930
	Japan	  	094753/94	  	2121896
	Norway	  	863806	  	175870
	*United States	  	06/695,309	  	
	*United States	  	06/797,472	  	
	United States	  	07/474,304	  	5,028,530

  

	*	Cases abandoned in favor of a continuing application. 

  
 -4- 

 SCHEDULE 2.2 

Transfer of XOMA Materials 
  

	1.	Plasmid DNA 

  

	2.	Plasmid Maps 

  

	3.	Expression Strain 

  

	4.	Lab-Scale Production 

  

	5.	Fermentation Production 

 SCHEDULE 2.4 

Form of Notice 
 XOMA owns a number
of patents covering various aspects of bacterial antibody expression and phage display. 
 XOMA has licensed these patents on a non-exclusive basis to
AFFIMED. 
 Under the license agreement with XOMA: 
  

	•	 	AFFIMED cannot provide evolution or phage display services or transfer related Immunoglobulin information to you without first showing you a redacted copy of its license from XOMA and this notice. 

 

	•	 	If you and AFFIMED enter into a written agreement by which you become a “AFFIMED Collaborator,” then you will be permitted to use AFFIMED evolution or phage display services and related Immunoglobulin and
information to research, develop and commercialize antibody Immunoglobulin. 

  

	•	 	Collaborators do not, however, have either the right to (a) produce commercial quantities of such antibodies using XOMA’s patented technology or (b) commercialize any results of research conducted by
AFFIMED. Rather, AFFIMED has the right to make Research quantities of antibodies using the XOMA patent rights. AFFIMED has the right to obtain licenses from XOMA on pre-negotiated terms, but subject to certain conditions. 

 

	•	 	Therefore, if you and AFFIMED enter into a written agreement, that agreement must contain certain provisions specified in the license agreement with XOMA, including: 

 

	 	•	 	Terms pursuant to which you, as the recipient of any transferred materials, would agree to abide by each of the limitations, restrictions and other obligations provided for by the license agreement with XOMA, including,
without limitation, the restrictions on use of such transferred materials for purposes other than Research. 

  

	 	•	 	A covenant not to use transferred materials for any purpose other than for Research purposes otherwise authorized by the license agreement with XOMA. 

 

	 	•	 	A provision that the “first sale” doctrine does not apply to any disposition of transferred materials. 

	 	•	 	An agreement by you to further dispose of transferred materials only to a third party who otherwise meets the definition of a “AFFIMED Collaborator” set forth in the license agreement with XOMA and who
executes a written agreement in which it undertakes all of the obligations applied to the transferring party. 

  
 -2- 

 SCHEDULE 5.1 

Library Construction Plan 

Project 
 Generation of ***** disease-specific custom
libraries 
 Objective 
 Affimed will generate *****
phage display libraries representing the antibody repertoire of patients suffering from different diseases. ***** 
 In detail, the project would comprise
the following activities: 
 ***** 

 SCHEDULE 6.1(b) 

Affimed Antibody Production Project 

ITEMS TO BE PROVIDED BY AFFIMED TO XOMA 

***** 
 XOMA WORK PLAN 

***** 

 ***** 

  
 -2- 

 ***** 

  
 -3- 

 CONFIDENTIAL 

Redacted Version 

SCHEDULE 7.2 

Redacted Form of this Agreement 

LICENSE AGREEMENT 
 This
License Agreement (this “Agreement”), effective as of September     , 2006 (the “Effective Date”), is entered into by and between XOMA Ireland Limited, a company with limited liability organized
under the laws of the Republic of Ireland having offices at Shannon Airport House, Shannon, County Clare, Ireland (with its Affiliates, “XOMA”), and Affimed Therapeutics AG, a company organized under the laws of the Federal Republic
of Germany, with offices at Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (with its Affiliates, “AFFIMED”). 

BACKGROUND 
 A. XOMA is
the owner or exclusive licensee of certain patent rights and know-how relating to bacterial cell expression, and AFFIMED wishes to acquire non-exclusive licenses under such patent rights and know-how; and 

B. XOMA is willing to grant AFFIMED non-exclusive licenses, on the terms and conditions set forth below, in order to permit AFFIMED to engage
in certain research, development and commercial activities; and 
 C. [Text intentionally omitted.); and 

D. [Text intentionally omitted.]; and 

E. [Text intentionally omitted.]. 

NOW, THEREFORE, in consideration of the promises and the mutual covenants hereinafter recited, the parties agree as follows: 

ARTICLE 1 
 DEFINITIONS 

In this Agreement, the following terms shall have the meanings set forth in this Article. 

1.1 “Affiliate” means any corporation or other entity which is directly or indirectly controlling, controlled by or under
common control with a party hereto. For purposes of this Agreement, “control” (including, with correlative meanings, the terms “controlled” and “controlling”) means the possession, directly or
indirectly, of the power 

 
to direct or cause the direction of the management or policies of the subject corporation or other entity, whether through the ownership of voting securities, by agreement or otherwise. 

1.2 “AFFIMED Collaborator” means a Third Party (a) either (i) from whom AFFIMED in-licenses a target or, solely as
provided for under Section 2.6, the variable domains of a ScFv subsequently incorporated into a Tandab or Flexibody for development and/or commercialization or (ii) with whom AFFIMED shares the economic risk of development or
commercialization of a target or Immunoglobulin being developed or commercialized on behalf of AFFIMED and (b) who, pursuant to the terms of a bona fide written collaboration agreement, in the AFFIMED Field, engages in Research with AFFIMED, is
the intended recipient of a Licensed Immunoglobulin or Licensed Immunoglobulin Information transferred from AFFIMED or is the party in a collaboration relating to one or more Tandabs who will develop, distribute or sell such Tandab(s) subject to
Article 3 of this Agreement; provided, however, that such person or entity shall not be deemed to be an AFFIMED Collaborator unless and until the requirements of Section 2.4 are complied with. No person or entity shall be permitted or
deemed to be an AFFIMED Collaborator if such person or entity, either as of the date of its written agreement with AFFIMED or thereafter, is or was (a) infringing any XOMA Patent Rights; (b) engaged in the research, development or
commercialization of an Immunoglobulin discovered, isolated or characterized by the use of Antibody Phage Display or under conditions which infringe any of the XOMA Patent Rights and/or (c) engaged in a Commercial Antibody Phage Display
Business or a Commercial Antibody Evolution Business during the term of this Agreement; provided, however, that, with respect to any variable domains in-licensed as provided in Section 2.6, as long as XOMA retains any rights it may have
with respect to the discovery of such variable domains, a Third Party engaged in a Commercial Antibody Phage Display Business or a Commercial Antibody Evolution Business may be an AFFIMED Collaborator with respect to such Tandab or Flexibody
pursuant to Section 2.6. 
 1.3 “AFFIMED Field” means (a) with respect to the rights granted in Section 2.1,
Research; (b) with respect to the rights granted in Section 2.5(a)(i), the diagnosis, treatment, prevention or prophylaxis of any human condition or disease; and (c) with respect to the rights granted in Section 2.5(a)(ii),
production in E. Coli, but not the commercialization of any composition of matter or article of manufacture so produced. The AFFIMED Field shall not include any Non-Approved Uses. 

1.4 [Text intentionally omitted.] 

1.5 “AFFIMED Product” means either a Flexibody or a Tandab manufactured in a prokaryote and containing a Licensed
Immunoglobulin. 
 1.6 [Text intentionally omitted.] 

1.7 [Text intentionally omitted.] 

  
 -2- 

 1.8 “Antibody Evolution” means the purposeful and/or guided alteration, either
by random mutation or other means, of one or more characteristics or attributes of an antibody and shall include, without limitation, directed mutagenesis, directed evolution or humanization of an Immunoglobulin. 

1.9 “Antibody Phage Display” means the use of Antibody Phage Display Materials, including, without limitation, to conduct
Research. 
 1.10 “Antibody Phage Display Materials” means (i) any collection or library of polynucleotide sequences
which encodes at least one Immunoglobulin and which is contained in bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or (ii) any collection or library of bacteriophage wherein an Immunoglobulin
is expressed as a fusion protein comprising an Immunoglobulin or at least a functionally operating region of an antibody variable region and an outer surface polypeptide of a bacteriophage. For the avoidance of doubt, and without limiting the
definition thereof, specifically excluded from the definition of Antibody Phage Display Materials are any article of manufacture or composition of matter suitable for display, expression or secretion of an Immunoglobulin in or from any organism or
system other than bacteria. With respect to AFFIMED, the term “Antibody Phage Display Materials” shall only include such materials or compositions of matter created by and under the exclusive control of Affimed Therapeutics AG and shall
not extend to any materials created by or under the control of any Third Party. 
 1.11 “Change in Control” means, with
respect to Affimed Therapeutics AG or XOMA Ltd., any transaction or series of transactions as a result of which any person or group (as defined under the U.S. Securities Exchange Act of 1934, as amended) becomes, directly or indirectly, the
beneficial owner of more than fifty percent (50%) of the total voting power of such entity’s equity securities or otherwise gains control of such entity, provided, however, that for the purposes of this definition, a “Change of
Control” shall not be deemed to occur upon the issuance or transfer of a controlling interest in the outstanding or issued stock of Affimed Therapeutics AG to bona fide financial investors who hold and control the stock solely for
investment purposes. 
 1.12 “Commercial Antibody Evolution Business” means, with respect to protein or other evolution
services, libraries, Immunoglobulins or materials, the out-licensing, commercial manufacture, sale, offer for sale, import for sale or export for sale of such protein or other evolution services, libraries, Immunoglobulins and materials, including,
without limitation, the sale of Antibody Evolution services. 
 1.13 “Commercial Antibody Phage Display Business” means,
with respect to immunoglobulin or antibody phage display services, libraries, Immunoglobulins or materials, the out-licensing, commercial manufacture, sale, offer for sale, import for sale or export for sale of such immunoglobulin or antibody phage
display services, libraries, Immunoglobulins and materials. 
 1.14 “Confidential Information” means any proprietary or
confidential information or material disclosed by a party to the other party pursuant to this 

  
 -3- 

 
Agreement, which is (a) disclosed in tangible form hereunder and is designated thereon as “Confidential” at the time it is delivered to the receiving party, or (b) disclosed
orally hereunder and identified as confidential or proprietary when disclosed and such disclosure of confidential information is confirmed in writing within thirty (30) days by the disclosing party. 

1.15 “Dispose” means to transfer, assign, lease, or in any other fashion dispose of control, ownership or possession, but
shall not mean to license or sell. “Disposition” shall have the correlative meaning. 
 1.16 [Text intentionally omitted.]

 1.17 “First Commercial Sale” means the initial transfer by AFFIMED (either directly or through a Third Party, including
without limitation any joint venture or similar arrangement in which AFFIMED or an AFFIMED Collaborator is a participant) of an Immunoglobulin subject to Section 2.5(b) for value and not for demonstration, testing or promotional purposes. 

1.18 “Flexibody” means a multimeric Fv-antibody, wherein each monomer of the Fv-antibody comprises the following features:
***** 
 1.19 “Immunoglobulin subject to Section 2.5(b)” means any composition of matter or article of manufacture,
including without limitation any diagnostic, prophylactic or therapeutic Immunoglobulin as to which AFFIMED elects to exercise its option right pursuant to Section 2.5(b), which (a) contains a Licensed Immunoglobulin; or (b) was
discovered or created by, arose out of or is related to the conduct of Research and/or use of a Licensed Immunoglobulin or Licensed Immunoglobulin Information; or (c) was discovered or is sold by or on behalf of AFFIMED or an AFFIMED
Collaborator under conditions which constitute utilization of the XOMA Patent Rights or use of the XOMA Know-How; or (d) is an Immunoglobulin as to which AFFIMED, on its own behalf, intends to manufacture in E. Coli, but as to which it
does not wish to obtain a license under Section 2.5(a)(i) 
 1.20 “Immunoglobulin” means any molecule, including
without limitation whole length immunoglobulin molecules (e.g., IgG, IgM, IgE, IgA and IgD molecules) and ScFv, Fv and Fab molecules, that has an amino acid sequence by virtue of which it specifically interacts with an antigen and wherein that amino
acid sequence consists essentially of a functionally operating region of an antibody variable region, including without limitation any naturally occurring or recombinant form of such a molecule. 

  
 -4- 

 1.21 “Licensed Immunoglobulin” means any Immunoglobulin discovered, isolated or
characterized by AFFIMED through the use of Licensed Materials, use of the XOMA Know-How, bacterial expression of a polypeptide, or use of any composition of matter claimed in, created by or involving the utilization of any method claimed in any
Valid Claim of the XOMA Patent Rights. 
 1.22 “Licensed Immunoglobulin Information” means any data, know-how or other
information relating, concerning or pertaining to a Licensed Immunoglobulin, including, without limitation, data, know-how or other information characterizing or constituting such Licensed Immunoglobulin’s polynucleotide or amino acid sequence,
purported function or utility, antigen binding affinity, or physical or biochemical properties. 
 1.23 “Licensed
Materials” means (a) any polynucleotide sequences created by and under the exclusive control of AFFIMED encoding an Immunoglobulin; (b) any expression vector created by or under the exclusive control of AFFIMED which encodes an
Immunoglobulin; or (c) any Antibody Phage Display Materials created by and under the exclusive control of AFFIMED. For the avoidance of doubt, and without expanding the definition thereof, specifically excluded from the definition of Licensed
Materials is any article of manufacture or composition of matter (i) made or used by a third party; (ii) constituting or useful for the display of Immunoglobulins in any organism other than bacteria; or (iii) created by or under the
control of any of the entity engaged in the licensing, manufacture, sale, offer for sale, import or export of antibody phage display services, Immunoglobulin or materials 

1.24 “Net Sales” means [Text intentionally omitted.]e. 

1.25 “Non-Approved Uses” means any and all uses not directly related to the AFFIMED Field and shall expressly include
(a) catalog or on-line sales of cloning or expression vectors, reagents or research or commercial kits; (b) expression of peptides or polypeptides, including Immunoglobulins or binding fragments thereof, on cell surfaces or viral surfaces;
(c) identification, selection or expression of proteins, reagents, and/or enzymes or compositions of matter for purely industrial uses or which are useful in the chemical industry and/or industrial manufacturing processes, including, without
limitation, the identification, selection or expression of catalytic antibodies; (d) plant science or agricultural applications; and (e) veterinary or animal health applications. 

1.26 “Research” means the identification, selection, isolation, purification, characterization, study and/or testing of
Immunoglobulins for any purpose, including, without limitation the discovery and development of human therapeutics or diagnostics and shall include Antibody Phage Display using Licensed Materials. Included within the definition of
“Research” shall be all in vitro screening or assays customarily performed in pre-clinical research. In the case of AFFIMED, “Research” shall not include (a) any effort to obtain economic value from a Third Party, including,
without limitation, from licensing to a Third Party any composition of matter or article of manufacture or any Licensed Immunoglobulin Information; or (b) commercial or industrial manufacture or any activities solely directed to the creation of
such capacities. 

  
 -5- 

 1.27 “Research Quantities” means those quantities of an Immunoglobulin
reasonably required for Research purposes. 
 1.28 “Tandab” means a bispecific tetravalent homodimeric single chain
antibody formed by the dimerisation of a single gene product comprising the heavy and light variable domains of two antibodies, A and B. The order of the domains from the N-terminus can be either AH-BL-BH-AL or AL-BH-BL-AH. 

1.29 “Third Party” means any person or entity other than AFFIMED or XOMA. 

1.30 “Valid Claim” means (i) a claim of an issued and unexpired patent included within [Text intentionally omitted.] the
XOMA Patent Rights [Text intentionally omitted.] which has not been held invalid in a final decision of a court of competent jurisdiction from which no appeal may be taken, and which has not been disclaimed or admitted to be invalid or unenforceable
through reissue or otherwise, or (ii) a claim of a pending patent application within [Text intentionally omitted.] the XOMA Patent Rights [Text intentionally omitted.]. 

1.31 “XOMA Development Partner” means a Third Party from whom XOMA either in-licenses a target for development and/or
commercialization or with whom XOMA shares the economic risk of development or commercialization of a target or Immunoglobulin being developed or commercialized on behalf of XOMA. 

1.32 “XOMA Know-How” means unpatented and/or unpatentable technical information, including ideas, concepts, inventions,
discoveries, data, designs, formulas, specifications, procedures for experiments and tests and other protocols, results of experimentation and testing, fermentation and purification techniques, and assay protocols, whether now existing or obtained
in the future (but as to future know-how, only as it relates to the materials transferred to AFFIMED pursuant to Section 2.2 hereof), owned by XOMA which XOMA has the right to license or sublicense and which may be necessary for the practice of
the XOMA Patent Rights or which would be misappropriated by the activities of AFFIMED, the AFFIMED Collaborators or the Development Partners of AFFIMED contemplated hereunder with respect to the materials transferred pursuant to Section 2.2
hereof but for this Agreement. XOMA Know-How shall not include the XOMA Patent Rights. All XOMA Know-How shall be confidential information of XOMA. 

1.33 “XOMA Licensee” means any third party to which XOMA grants or transfers any rights in respect of any composition of
matter or article of manufacture or a third party from whom XOMA in-licenses a target or Immunoglobulin, with whom XOMA collaborates to develop an Immunoglobulin, or who is working with or on behalf of XOMA. 

1.34 “XOMA Patent Rights” means the patent applications and patents listed on Schedule 1.34 hereto and, solely to the
extent any Valid Claim would cover or be included in the license grants provided for herein, all divisions, continuations, 

  
 -6- 

 
continuations-in-part, applications claiming priority thereto, and substitutions thereof; all foreign patent applications corresponding to the preceding applications; all U.S. and foreign patents
issuing on any of the preceding applications, including extensions, reissues and re-examinations; and any patents or patent applications, whether now existing or obtained in the future, owned or controlled by XOMA containing a claim that is
dominating over the foregoing patent rights (i.e., is necessarily infringed by the practicing of a claim in one of the foregoing applications). 

1.35 Additional Defined Terms. The following terms are defined in the corresponding sections indicated below: 

 

			
	 Term
	  	 Section

		
	[Text intentionally omitted.]	  	[Text intentionally omitted.]
	ICDR	  	10.13(a)
	In-License Request	  	2.6
	Option	  	2.5(a)
	[Text intentionally omitted.]	  	[Text intentionally omitted.]
	Records	  	2.8(b)
	Research License	  	2.1
	[Text intentionally omitted.]	  	[Text intentionally omitted.]
	Title XI	  	10.9
	Transferred Materials	  	2.4(a)
	[Text intentionally omitted.]	  	[Text intentionally omitted.]
	XOMA Authorized Site	  	2.7
	[Text intentionally omitted.]	  	[Text intentionally omitted.]

 1.36 Interpretation. 

(a) Whenever any provision of this Agreement uses the term “including” (or “includes”), such term shall be deemed to mean
“including without limitation” and “including but not limited to” (or “includes without limitations” and “includes but is not limited to”) regardless of whether the words “without limitation” or
“but not limited to” actually follow the term “including” (or “includes”); 
 (b) The recitals set forth at
the start of this Agreement, along with the Schedules to this Agreement, and the terms and conditions incorporated in such recitals and Schedules shall be deemed integral parts of this Agreement and all references in this Agreement to this Agreement
shall encompass such recitals and Schedules and the terms and conditions incorporated in such recitals and Schedules; 
 (c) Unless
otherwise provided, all references to Sections, Articles and Schedules in this Agreement are to Sections, Articles and Schedules of and to this Agreement; 

(d) All references to days, months, quarters or years are references to calendar days, calendar months, calendar quarters or calendar years;
and 
 (e) The above definitions are intended to encompass the defined terms in both the singular and plural forms. 

  
 -7- 

 ARTICLE 2 

XOMA GRANT OF RIGHTS TO AFFIMED 

2.1 Research License. XOMA hereby grants to AFFIMED a worldwide, fully paid-up, royalty free, non-exclusive, non-transferable license,
on its own behalf and on behalf of an AFFIMED Collaborator, and without the right to sublicense, under the XOMA Patent Rights and the XOMA Know-How to make and use Licensed Materials to conduct Research, including Antibody Phage Display (the
“Research License”). For the sake of clarity, the Research License is personal to AFFIMED and is to be used on behalf of any AFFIMED Collaborator only in respect of or in connection with the activities that such AFFIMED Collaborator
is engaged in that are the basis for meeting the definition of AFFIMED Collaborator and not any other activities. It is understood between the Parties that the license granted by this Section 2.1 is a “research only” license and that,
unless and until the Option is exercised in accordance with Section 2.5(a), AFFIMED shall have no rights to commercialize, either directly or indirectly, any Immunoglobulin or Licensed Immunoglobulin Information, arising from the activities
subject to this license grant. 
 2.2 XOMA Transfer to AFFIMED. Within thirty (30) days of the Effective Date, XOMA shall
transfer to AFFIMED, at a mutually agreed place and time, the materials identified on Schedule 2.2. For the avoidance of doubt, such materials shall constitute XOMA Know-How. Technology is included in the initial consideration to XOMA under
this Agreement and includes up to two person-days of XOMA scientific staff time at XOMA’s facilities for up to two (2) AFFIMED employees within 9 months from the Effective Date (which period may be extended by mutual consent of the
parties, which consent shall not be unreasonably withheld). Thereafter, AFFIMED will be able to consult with XOMA scientific staff at $1 ,500/person-day (based on an eight hour day) beyond the two person-days. 

2.3 No Implied Rights. Only the rights and licenses granted pursuant to the express terms of this Agreement shall be of any legal force
or effect. No license or other rights shall be deemed to have been granted to AFFIMED or an AFFIMED Collaborator other than as expressly provided for in this Agreement. For the avoidance of doubt, the grants of rights made pursuant to
Section 2.1 and, upon exercise of the Option, Section 2.5, do not include, and expressly exclude, the following: 
  

	 	(a)	any right or license to engage in any activities on behalf of or in collaboration with any Third Party, other than an AFFIMED Collaborator; 

 

	 	(b)	except upon proper exercise of the Option with respect to each Licensed Immunoglobulin, any right or license to make or have made any amount, other than Research Quantities, of a Licensed Immunoglobulin by practicing
the XOMA Patent Rights or the XOMA Know-How; 

  
 -8- 

	 	(c)	any release or right to release any Third Party, including an AFFIMED Collaborator, from any claim of infringement under the XOMA Patent Rights or misappropriation of the XOMA Know-How; 

 

	 	(d)	does not constitute a release or waiver of past, present or future infringement of the XOMA Patent Rights or misappropriation of the XOMA Know-How by AFFIMED or any Third Party; 

 

	 	(e)	any right or license under the XOMA Patent Rights or XOMA Know-How to sell, lease, license, transfer or dispose of the ownership or possession to a Third Party of any composition of matter or article of manufacture
suitable for the conduct of Antibody Evolution or Antibody Phage Display; and/or 

  

	 	(f)	any right or license to cause any Third Party to use Antibody Phage Display Materials to identify, select, characterize, study or test a polypeptide, including but not limited to an Immunoglobulin. 

2.4 Transfer Restrictions. 

(a) AFFIMED shall not (i) undertake any Research activities, including any Antibody Phage Display, on behalf of a Third Party or
(ii) Dispose of a Licensed Immunoglobulin, Licensed Immunoglobulin Information or any Immunoglobulin arising out of the practice of any method within the scope of the XOMA Patent Rights (“Transferred Materials”) to any Third
Party until (in the case of either clause (i) or clause (ii)) such time as it has provided to such Third Party the redacted copy of this Agreement referred to in Section 7.2 and the form of notice set out at Schedule 2.4. 

(b) AFFIMED shall enter into a written arrangement with any Third Party with respect to any activities as to which it or such Third Party does
or intends to claim the benefits of any of the licenses or other grants provided for in this Article 2, and such written arrangement shall contain provisions (i) pursuant to which the recipient of any Transferred Materials agrees to abide by
each of the limitations, restrictions and other obligations provided for by this Agreement, including without limitation the restrictions on use of Transferred Materials for purposes other than Research and the obligations of Section 2.5(b);
(ii) implementing a covenant not to use Transferred Materials for any purpose other than for Research purposes otherwise authorized by this Agreement; (iii) providing that the “first sale” doctrine does not apply to any
Disposition; and (iv) permitting an AFFIMED Collaborator to further Dispose of Transferred Materials only to a Third Party who otherwise meets the definition of an AFFIMED Collaborator and who executes a written agreement in which it undertakes
all of the obligations applied to the transferring party. XOMA shall be, and the agreements subject to this Section 2.4 shall provide that XOMA shall be, an intended third party beneficiary with respect to the foregoing provisions. 

  
 -9- 

 2.5 License Option. 

(a) So long as the provisions of Section 2.5(b) are complied with and AFFIMED and, as applicable, any AFFIMED Collaborator, is not
otherwise in breach of any material provision of this Agreement, upon ***** prior written notice, on an Immunoglobulin by Immunoglobulin basis, XOMA hereby agrees to grant (the “Option”) a worldwide, non-exclusive, nontransferable
license to AFFIMED, on its own behalf and on behalf of an AFFIMED Collaborator, under the XOMA Patent Rights and the XOMA Know-How in the AFFIMED Field to: 
  

	 	(i)	make or have made (in a prokaryote and without use of a discistronic construct), use, sell, offer to sell, import and otherwise commercialize those Licensed Immunoglobulins discovered, isolated or optimized under the
Research License and as to which AFFIMED or the AFFIMED Collaborator pays the amounts, including royalties on Net Sales, due under Article 3; and/or 

  

	 	(ii)	to make in E. Coli, solely on its own behalf, clinical and commercial supplies of any Immunoglobulin discovered or isolated exclusively by AFFIMED or by AFFIMED on behalf of an AFFIMED Collaborator and as to
which AFFIMED pays the amounts, including royalties on Net Sales, due under Article 3. 

 XOMA shall not be obligated to grant the license
provided for in this Section 2.5(a) unless the other provisions of this Agreement, including Section 2.5(b), are complied with. 

(b) For each Licensed Immunoglobulin as to which AFFIMED wishes to obtain a license pursuant to Section 2.5(a), AFFIMED shall provide to
XOMA a written notice which identifies the specific Immunoglobulin for which AFFIMED seeks such a license, the target to which such Immunoglobulin binds, a designation as to whether such Immunoglobulin was discovered or isolated pursuant to the
Research License, a written certification that AFFIMED or as applicable an AFFIMED Collaborator, for each Licensed Immunoglobulin, has complied with all of the provisions of this Agreement and a notification as to whether AFFIMED seeks a license
pursuant to Section 2.5(a)(i), Section 2.5(a)(ii) or both. Upon receipt of such written notice, XOMA shall, pursuant to its then most current standard non-economic terms, grant the applicable license, unless (i) such Immunoglobulin or
target is the subject of an exclusive license granted by XOMA to a Third Party or (ii) XOMA has contemporaneous written proof of a bona fide development program with respect to any Immunoglobulin binding to the same target as the Immunoglobulin
as to which the request for license grant has been made. 
 (c) Upon the successful exercise of an Option to an Immunoglobulin, for so long
as the applicable royalty and other payments are made, XOMA covenants that it shall not initiate or permit any Third Party over whom it has control to initiate or assist in any way in the initiation or prosecution of any action asserting a claim of
infringement under the XOMA Patent Rights or misappropriation of the XOMA Know-How against AFFIMED or any AFFIMED Collaborator to the extent reasonably necessary to permit the authorized making, having made, use, sale, offer for sale or
commercialization of any 

  
 -10- 

 
Licensed Immunoglobulin subject to a grant under Section 2.5(a){i) and the making and having made of any Immunoglobulin subject to a grant under Section 2.5(a)(ii). The covenant not to
sue provided by this Section 2.5(c): 
  

	 	(i)	shall become void and without effect as to any entity or person who claims its benefit but fails to materially discharge or comply with any term of its written agreement with AFFIMED provided for in Section 2.4(b);

  

	 	(ii)	is personal to AFFIMED and any such AFFIMED Collaborator and cannot be assigned or transferred; 

  

	 	(iii)	as to any AFFIMED Collaborator, does not extend to making, using, selling, having made or importing Antibody Phage Display Materials or any compositions of matter or articles of manufacture suitable for Antibody Phage
Display; and 

  

	 	(iv)	does not constitute a release or waiver of past, present or future infringement of the XOMA Patent Rights or misappropriation of the XOMA Know-How by AFFIMED or any Third Party, including, without limitation, any
AFFIMED Collaborator acting outside of the scope of the written agreement with AFFIMED provided for in Section 2.4(b). 

(d) AFFIMED covenants not to commercialize, license or develop any Immunoglobulin discovered under the Research License without submitting
such Immunoglobulin to XOMA for a license pursuant to this Section 2.5. 
 2.6 Third Party Variable Domains. (a) From time
to time, but no more often than once per quarter, AFFIMED may, on its own behalf or on behalf of a Third Party who otherwise qualifies as an AFFIMED Collaborator and who will be an AFFIMED Collaborator if the other provisions of this
Section 2.6 are met, request in writing that XOMA permit AFFIMED to format a variable domain not discovered by AFFIMED into a Tandab or a Flexibody and, as applicable, exercise its Option rights pursuant to Section 2.5(a)(i) and (ii). Such
writing (the “In-License Request”) shall specify: (i) the potential AFFIMED Collaborator and any Third Party with a financial interest in the variable domains or the proposed AFFIMED Product; (ii) the variable domains;
(iii) the target as to which such variable domains are directed; (iv) whether the Option request extends to the rights provided for by Sections 2.5(a)(i), 2.5(a)(ii) or both; (v) the format such variable domains shall be converted
into (Tandab or Flexibody); and (vi) a statement as to whether, to the knowledge of AFFIMED after diligent investigation, such variable domains were discovered, identified, characterized, optimized and/or altered using the XOMA Patent Rights or
bacterial expression, including without limitation via Antibody Phage Display. Upon such request, and until the end of Phase II (or equivalent) clinical trials, such Tandab or Flexibody shall be deemed to be an “AFFIMED Product” under this
Agreement, provided, however, that if no In-License Request is made prior to initiation of Phase II or if a license is not subsequently consummated, then any status as an AFFIMED Product shall, retroactively, be cancelled and the Tandab or
Flexibody will be deemed as to have never been licensed under this Agreement. 

  
 -11- 

 (b) Within ***** of the receipt of the In-License Request, XOMA, pursuant to the same conditions
as Section 2.5(b), shall, in writing, indicate whether each such proposed AFFIMED Product is accepted to be a Licensed Immunoglobulin. For each such proposed AFFIMED Product accepted as a Licensed Immunoglobulin, the following conditions shall
apply: (i) XOMA, AFFIMED and the Third Party must agree to the form of and execute a written license agreement under which XOMA shall grant, pursuant to its then most current noneconomic terms, the applicable license; (ii) AFFIMED and the
Third Party, if applicable, must negotiate in good faith for and pay cash consideration to XOMA to obtain a release for any past infringement of the XOMA Patent Rights by such Third Party; and (iii) such license shall, as applicable, contain
licenses or grants to XOMA and any XOMA Development Partner or XOMA Licensee under those rights as may be under the control of or sublicenseable from such Third Party in a form equivalent to the license grant and rights given by AFFIMED to XOMA
pursuant to Article 4 of this Agreement. 
 (c) AFFIMED’s rights under this Section 2.6 shall apply to no more than five
(5) different Tandabs or Flexibodies. 
 2.7 XOMA Authorized Site. AFFIMED may “have made” Licensed Immunoglobulins or
Immunoglobulins subject to Section 2.5(a)(ii) under the XOMA Patent Rights and the XOMA Know-How in the AFFIMED Field at a XOMA Authorized Site. All activities at a XOMA Authorized Site in the AFFIMED Field shall be pursuant to a contract
manufacturing agreement containing all of the applicable provisions of this Agreement and shall be for the sole benefit of AFFIMED. XOMA shall be provided a reasonable opportunity prior to execution of any such agreement to review a redacted version
of such agreement that is sufficient to confirm the foregoing obligations, and AFFIMED shall give due consideration to any comments of XOMA thereon. Prior to permitting or initiating any activity at a XOMA Authorized Site in the AFFIMED Field,
AFFIMED covenants that such XOMA Authorized Site shall (i) agree in advance in writing to be bound for the benefit of XOMA by all of the provisions of this Agreement; (ii) agree to implement such customary and usual safeguards as may be
necessary to insure that the XOMA Know-How is accessed and utilized on a “need to know” basis only; and (iii) agree that such XOMA Authorized Site shall undertake the activities solely on behalf of AFFIMED and as a result of such
activities shall not claim any license or right under the XOMA Patent Rights or XOMA Know-How for the benefit of itself or any other Third Party. AFFIMED shall remain fully and primarily liable for all actions of, or failures to act by, such XOMA
Authorized Site in connection therewith and agrees to hold XOMA harmless with respect thereto without qualification. For the avoidance of doubt, AFFIMED acknowledges that no such delegation of rights shall relieve AFFIMED of its responsibilities for
performance of any of its obligations hereunder. For the purposes of this Section 2.7, a “XOMA Authorized Site” shall mean one or more contract manufacturers designated in writing from time to time by XOMA. The terms and
conditions of any agreement between XOMA and the XOMA Authorized Site shall also apply to any activities undertaken on behalf of AFFIMED pursuant to this Section 2.7. No such entity or person shall be deemed to be a XOMA Authorized Site unless
and until, as to each Licensed Immunoglobulin or Immunoglobulin subject to Section 2.5(b), as applicable, to be produced pursuant to this Section 2.7, it enters into a legally binding 

  
 -12- 

 
agreement with AFFIMED that implements the provisions of this Section 2.7, naming XOMA as a third party beneficiary of those provisions of such agreement that pertain to confidentiality and
restrictions on transfer and use of Licensed Immunoglobulins, XOMA Patent Rights and XOMA Know-How provided for in this Agreement. 
 2.8
Reports, Records and Audits. 
 (a) ***** after the end of each calendar quarter, commencing with the first calendar quarter
commencing after the Effective Date, AFFIMED shall deliver to XOMA a written report which shall specify the name, address and contact person for each and every potential and actual AFFIMED Collaborator and any person or entity with whom AFFIMED has
engaged in Research, who has received any Transferred Materials or, in the case of the exercise of the Option in accordance with Section 2.5(a), who has received any clinical or commercial supplies manufactured by AFFIMED or with whom AFFIMED
is engaged in the commercialization of an Immunoglobulin subject to the Option of Section 2.5(a). The reports delivered by AFFIMED to XOMA pursuant to this Section 2.8(a) shall be Confidential Information of AFFIMED. 

(b) AFFIMED shall maintain records fully and properly reflecting those activities to be reported to XOMA pursuant to Section 2.8(a) (the
“Records”), in sufficient detail and in good scientific manner appropriate for patent, regulatory and manufacturing purposes for at least three (3) years. Upon the written request of XOMA and not more than once in each calendar
year, AFFIMED shall permit an independent consultant appointed by XOMA and subject to customary confidentiality restrictions, at XOMA’s expense, to have access during normal business hours to such of the records of AFFIMED as may be reasonably
necessary to verify compliance with the terms of this Agreement, as well as the accuracy of the reports hereunder. AFFIMED shall certify any statements by AFFIMED personnel as to their accuracy and correctness. 

2.9 Ownership; Enforcement. At all times XOMA will retain ownership of the XOMA Know-How and the XOMA Patent Rights and may use and
commercialize such XOMA Know-How and XOMA Patent Rights itself or with any Third Party. XOMA retains the right, at its sole discretion, to enforce, maintain and otherwise protect the XOMA Know-How and the XOMA Patent Rights. In addition to the
requirements of Section 2.8, AFFIMED shall give XOMA prompt notice of misappropriation of any of the XOMA Know-How, or any infringement of any of the XOMA Patent Rights, by a Third Party which comes to AFFIMED’ s attention during the term
of this Agreement. 
 2.10 No Admission of Infringement. The execution of this Agreement is not an admission that any action by
AFFIMED or AFFIMED Product either infringed or is infringing the XOMA Patent Rights and AFFIMED reserves all of its rights with respect to the practice of any technology and the production of any composition of matter or article of manufacture
unrelated to the XOMA Patent Rights or the XOMA Know-How. 

  
 -13- 

 ARTICLE 3 

PAYMENTS 
 3.1 [Text
intentionally omitted.] 
 3.2 [Text intentionally omitted.] 

3.3 Payments; Currency. All payments due hereunder shall be paid by wire transfer in United States dollars in immediately available
funds to an account designated by XOMA. Payments required pursuant to Section 3.1 hereof shall be due and payable to XOMA when the corresponding milestone is achieved and shall be paid within thirty (30) days thereof. Payments required
pursuant to Section 3.2 hereof shall be due and payable to XOMA when the corresponding Net Sales are received by AFFIMED, the AFFIMED Collaborator, or any Joint Venture in which AFFIMED is a participant and shall be paid within sixty
(60) days of the end of each calendar quarter. If any currency conversion shall be required in connection with the payment of any royalties hereunder, such conversion shall be made by using the exchange rate for the purchase of U.S. dollars
quoted in the U.S. version of the Wall Street Journal on the last business day of the calendar quarter to which such payments relate. 
 3.4
Payment Reports. AFFIMED shall make a written report to XOMA within ***** of the achievement of each of the milestones set forth in Section 3.1, stating in each such report the Licensed Immunoglobulin or Immunoglobulin to which such
milestone relates and the specific milestone achieved, including the relevant agency or other regulatory body. After the First Commercial Sale of a Licensed Immunoglobulin or Immunoglobulin subject to Section 2.5(b) on which royalties are
required to be paid hereunder, AFFIMED shall make quarterly written reports to XOMA within ***** after the end of each calendar quarter, stating in each such report, the description and aggregate Net Sales of each Licensed Immunoglobulin or Product
sold during the calendar quarter. XOMA shall treat all such reports as Confidential Information of AFFIMED Concurrently with the making of such reports, AFFIMED or, as applicable, the AFFIMED Collaborator, shall pay XOMA the amounts specified in
Sections 3.1 and 3.2 hereof. 
 3.5 Payment Records and Inspection. AFFIMED and each AFFIMED Collaborator shall keep complete, true
and accurate books of account and records for the purpose of determining the amounts payable under this Agreement. Such books and records shall be kept at the principal place of business of AFFIMED for at least ***** following the end of the
calendar quarter to which they pertain. Upon the written request of XOMA and not more than once in each calendar year, AFFIMED shall permit an independent consultant appointed by XOMA and reasonably acceptable to AFFIMED to have access during normal
business hours to such of the records as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any year ending not more than ***** prior to the date of such request. The consultant shall disclose to XOMA only the
results and conclusions of its review and the specific details concerning any discrepancies. No other information shall be shared by the consultant 

  
 -14- 

 
without the prior consent of AFFIMED unless disclosure is required by law, regulation or judicial order. [Text intentionally omitted.] Any underpayments or unpaid amounts discovered by such
inspections or otherwise will be paid promptly by AFFIMED, with interest from the date(s) such amount(s) were due at an annual rate equal to the lesser of the prime rate reported by the Bank of America plus ***** or the highest interest rate
permitted under applicable law. 
 3.6 Commercially Reasonable Efforts. AFFIMED will use commercially reasonable efforts until
clinical phase III to exploit the XOMA Patent Rights and maximize the amounts available to be shared with XOMA pursuant to this Article 3. 

ARTICLE 4 
 AFFIMED GRANT OF
RIGHTS TO XOMA 
 [Text intentionally omitted.] 

ARTICLE 5 
 XOMA LIBRARY PROJECT

 [Text intentionally omitted.] 

ARTICLE 6 
 XOMA PROCESS 

DEVELOPMENT PROJECT 
 [Text
intentionally omitted.] 
 ARTICLE 7 

CONFIDENTIALITY 
 7.1
Confidential Information. Except as expressly provided herein, the parties agree that, for the term of this Agreement and for ***** thereafter, the receiving party shall keep completely confidential and shall not publish or otherwise disclose
and shall not use for any purpose except for the purposes contemplated by this Agreement any Confidential Information furnished to it by the disclosing party hereto, except to the extent that it can be established by the receiving party by written
proof that such Confidential Information: 
  

	 	(a)	was already known to the receiving party, other than under an obligation of confidentiality, at the time of disclosure; 

  
 -15- 

	 	(b)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving party; 

  

	 	(c)	became generally available to the public or otherwise part of the public domain after its disclosure other than through any act or omission of the receiving party in breach of this Agreement; or 

 

	 	(d)	was subsequently lawfully disclosed to the receiving party by a person other than a party hereto. 

7.2 Permitted Use and Disclosures. Each party hereto may use or disclose information disclosed to it by the other party to the extent
such use or disclosure is reasonably necessary in complying with applicable law or government regulations or conducting clinical trials; provided, however, that if a party is required to make any such disclosure of another party’s
Confidential Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the latter party of such disclosure and, will use its reasonable efforts to secure confidential treatment of such information
prior to its disclosure (whether through protective orders or otherwise). Attached hereto as Schedule 7.2 is a redacted copy of this Agreement which AFFIMED shall be free, without obtaining any consent from XOMA, to provide to Third Parties
who indicate an interest in becoming an AFFIMED Collaborator. 
 7.3 Confidential Terms. Except as expressly provided herein, each
party agrees not to disclose any terms of this Agreement to any Third Party without the consent of the other party; provided, that disclosures may be made as required by securities or other applicable laws, or to a party’s accountants,
attorneys and other professional advisors. 
 7.4 Agreement Announcement. The parties hereby agree to the release of a press release
in the form attached hereto as Schedule 7.4 upon full execution of this Agreement and that the fact of the consummation of this Agreement shall be deemed to be in the public domain. 

ARTICLE 8 
 REPRESENTATIONS AND
WARRANTIES 
 8.1 Representations and Warranties. 

(a) XOMA represents and warrants to AFFIMED that: (i) it is the sole and exclusive owner or exclusive licensee of all right, title and
interest in the XOMA Patent Rights; (ii) XOMA has the legal right, authority and power to enter into this Agreement; (iii) this Agreement shall constitute a valid and binding obligation of XOMA enforceable in accordance with its terms; and
(iv) the performance of obligations under this Agreement by XOMA shall not result in a breach of any agreements, contracts or other arrangements to which it is a party. 

  
 -16- 

 (b) AFFIMED represents and warrants to XOMA that: (i) [Text intentionally omitted.];
(ii) AFFIMED has the legal right, authority and power to enter into this Agreement; (iii) this Agreement shall constitute a valid and binding obligation of AFFIMED enforceable in accordance with its terms; (iv) the performance of
obligations under this Agreement by AFFIMED shall not result in a breach of any agreements, contracts or other arrangements to which it is a party and (v) [Text intentionally omitted.]. 

8.2 Disclaimer. Nothing in this Agreement is or shall be construed as: 

 

	 	(a)	A warranty or representation by XOMA [Text intentionally omitted.] as to the validity or scope of any claim or patent within the XOMA Patent Rights [Text intentionally omitted.]; 

 

	 	(b)	A warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of any patent · rights or other intellectual
property right of any Third Party; 

  

	 	(c)	An obligation to bring or prosecute actions or suits against Third Parties for infringement of any of the XOMA Patent Rights [Text intentionally omitted.]; 

 

	 	(d)	An obligation to maintain any patent or to continue to prosecute any patent application included within the XOMA Patent Rights [Text intentionally omitted.] in any country; or 

 

	 	(e)	Granting by implication, estoppel, or otherwise any licenses or rights under patents or other rights of XOMA, AFFIMED or Third Parties, regardless of whether such patents or other rights are dominant or subordinate to
any patent within the XOMA Patent Rights [Text intentionally omitted.]. 

 8.3 No Other Warranties. EXCEPT AS OTHERWISE
SET FORTH IN SECTION 8.1 ABOVE, NEITHER PARTY HERETO MAKES ANY WARRANTIES WITH RESPECT TO ANY OF THE PATENT RIGHTS, MATERIALS OR KNOW-HOW LICENSED HEREUNDER, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND
EACH PARTY SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, OF FITNESS FOR A PARTICULAR PURPOSE, OF VALIDITY OF SUCH PATENT RIGHTS, MATERIALS OR KNOW-HOW, OR OF NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY
THIRD PARTY. 

  
 -17- 

 ARTICLE 9 

TERM AND TERMINATION 
 9.1
Term. Subject to Sections 9.4 and 9.5 hereof, the term of this Agreement will commence on the Effective Date and (a) with regard to the license and other rights granted to AFFIMED and any AFFIMED Collaborators by XOMA pursuant to Article
2, this Agreement shall remain in full force and effect until the last to expire of the XOMA Patent Rights or the tenth anniversary of the First Commercial Sale of the last Immunoglobulin subject to Section 2.5(b) to be launched, whichever is
later, unless earlier terminated by XOMA pursuant to Section 9.2 or 9.3; and (b) [Text intentionally omitted.]. 
 9.2
Termination for Material Breach. With regard to (a) the license and other rights granted to AFFIMED and any AFFIMED Collaborators by XOMA pursuant to Article 2, or (b) [Text intentionally omitted.], this Agreement may be terminated
by the non-breaching party upon any material breach by XOMA or AFFIMED, as the case may be, of any material obligation or condition of the Agreement, in either case effective ***** after giving notice to the breaching party of such termination in
the case of a payment breach and ***** after giving written notice to the breaching party of such termination in the case of any other breach, which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such
breach is cured or shown to be non-existent within the aforesaid ***** or *****, the notice shall be deemed automatically withdrawn and of no effect and the notifying party shall provide written notice to the breaching party of the withdrawal.
A termination of the breaching party’s rights and licenses pursuant to this Section 9.2 shall not effect the non-breaching party’s rights and licenses, which shall continue until otherwise terminated in accordance with this Agreement.

 9.3 Termination for Insolvency. If voluntary or involuntary proceedings by or against either party are instituted in bankruptcy
under any insolvency law, or a receiver or custodian is appointed for either party, or proceedings are instituted by or against either party for corporate reorganization or the dissolution of such party, which proceedings, if involuntary, shall not
have been dismissed within ***** after the date of filing, or if either party makes an assignment for the benefit of creditors, or substantially all of the assets of either party are seized or attached and not released within ***** thereafter, the
other party may immediately terminate this Agreement effective upon notice of such termination. 
 9.4 Effect of Termination. 

(a) Termination of this Agreement shall not release any party hereto from any liability which, at the time of such termination, has already
accrued to the other party or which is attributable to a period prior to such termination nor preclude either party from pursuing any rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement. It
is understood and agreed that monetary damages may not be a sufficient remedy for any breach of this Agreement and that the 

  
 -18- 

 
non-breaching party may be entitled to injunctive relief as a remedy for any such breach. Such remedy shall not be deemed to be the exclusive remedy for any such breach of this Agreement, but
shall be in addition to all other remedies available at law or in equity. 
 (b) Upon any termination of this Agreement, AFFIMED and XOMA
shall promptly return to the other party all Confidential Information received from the other party (except that each party may retain one copy for its files solely for the purpose of determining its rights and obligations hereunder). 

(c) Except as expressly provided in this Article 9, all licenses granted under Article 2 hereof shall terminate and be of no further effect
upon the termination of this Agreement. 
 (d) [Text intentionally omitted.] 

9.5 Survival. Sections 2.8, 2.9, 2.10, 3.1 through 3.5, [Text intentionally omitted.], 9.1, 9.2, 9.4 and 9.5, and Articles 1, [Text
intentionally omitted.], 7, 8 and 10, of this Agreement shall survive any termination hereof. 
 ARTICLE 10 

MISCELLANEOUS PROVISIONS 
 10.1
Governing Laws. This Agreement and any dispute, including without limitation any arbitration, arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the laws of the state of New Y or~
without reference to conflicts of laws principles. 
 10.2 Assignment. Neither party may transfer or assign this Agreement, directly
or indirectly, or any of its rights hereunder without the prior written consent of the other party, other than (a) to one or more Affiliates, (b) to a successor of XOMA Ltd. under a Change in Control of XOMA Ltd., or (c) in the case
of XOMA, to a Third Party in connection with the transfer or sale of all or substantially all of its business relating to Immunoglobulins. Any such attempted transfer or assignment in violation of this Section 10.2 shall be void;
provided that in the event of a permitted Change in Control, the original party’s (or its successor’s) obligations hereunder shall continue. This Agreement shall be binding upon and inure to the benefit of the parties and their
permitted successors and assigns. 
 10.3 Certain Changes in Control. (a) Notwithstanding any other provision of this Agreement
to the contrary, solely at XOMA’s option, unless the provisions of Section 10.3(b) are met, the license and other rights granted to AFFIMED and any AFFIMED Collaborators pursuant to Article 2 shall automatically terminate, in whole or in
part, without further action by the parties, in the event of a transaction or series of related transactions in which AFFIMED is a party and which results in a Change in Control of AFFIMED or the sale of all or substantially all of the antibody
discovery or assets used for Antibody Phage by AFFIMED. 

  
 -19- 

 (b) [Text intentionally omitted.] 

10.4 Waiver. No waiver of any rights shall be effective unless consented to in writing by the party to be charged and the waiver of any
breach or default shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 
 10.5
Severability. In the event that any provisions of this Agreement are determined to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement shall remain in full force and effect without said provision.

 10.6 Notices. All notices, requests and other communications hereunder shall be in writing and shall be delivered or sent in each
case to the respective address specified below, or such other address as may be specified in writing to the other party hereto, and shall be effective on receipt: 
  

			
	AFFIMED:	 	 Affimed Therapeutics AG
 Technologiepark

Im Neuenheimer Feld 582
 69120 Heidelberg

Germany
 Attn:  Chief Executive Officer

		
	XOMA:	 	 XOMA Ireland Limited
 Shannon Airport House

Shannon, County Clare
 Ireland

Attn:  Company Secretary

	
	with a copy (which shall not constitute notice) to:
		
		 	 Cahill Gordon & Reindel LLP 

80 Pine Street
 New York, NY 10005

U.S.A.
 Attn:  Geoffrey E. Liebmann

 10.7 Independent Contractors. Both parties are independent contractors under this Agreement. Nothing
contained in this Agreement is intended nor is to be construed so as to constitute XOMA or AFFIMED as partners or joint venturers with respect to this Agreement. Except as expressly provided herein, neither party shall have any express or implied
right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any other contract, agreement, or undertaking with any third party. 

10.8 Compliance with Laws. In exercising their rights under this license, the parties shall comply in all material respects with the
requirements of any and all applicable laws, regulations, rules and orders of any governmental body having jurisdiction over the exercise of rights under this Agreement. 

  
 -20- 

 10.9 Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by
one party to the other are, for all purposes of Section 365(n) of Title XI of the United States Code (“Title XI’), licenses of rights to “intellectual property” as defined in Title XI. During the term of this
Agreement each party shall create and maintain current copies to the extent practicable of all such intellectual property. If a bankruptcy proceeding is commenced by or against one party under Title XI, the other party shall be entitled to a copy of
any and all such intellectual property and all embodiments of such intellectual property, and the same, if not in the possession of such other party, shall be promptly delivered to it (a) upon such party’s written request following the
commencement of such bankruptcy proceeding, unless the party subject to such bankruptcy proceeding, or its trustee or receiver, elects within thirty (30) days to continue to perform all of its obligations under this Agreement, or (b) if
not delivered as provided under clause (a) above, upon such other party’s request following the rejection of this Agreement by or on behalf of the party subject to such bankruptcy proceeding. If a party has taken possession of all
applicable embodiments of the intellectual property of the other party pursuant to this Section 10.9 and the trustee in bankruptcy of the other party does not reject this Agreement, the party in possession of such intellectual property shall
return such embodiments upon request. If a party seeks or involuntarily is placed under Title XI and the trustee rejects this Agreement as contemplated under 11 U.S.C. 365(n)(l), the other party hereby elects, pursuant to Section 365(n) of
Title XI, to retain all rights granted to it under this Agreement to the extent permitted by law. 
 10.10 Use of Name. Neither party
shall use the name or trademarks of the other party, except to the extent that a party is permitted to use the Confidential Information of the other party pursuant to Article 7, without the prior written consent of such other party. 

10.11 Further Actions. Each party agrees to execute, acknowledge and deliver such further instruments, and do such other acts, as may
be necessary and appropriate in order to carry out the purposes and intent of this Agreement. 
 10.12 Entire Agreement; Amendment.
This Agreement constitutes the entire and exclusive Agreement between the parties with respect to the subject matter hereof and supersedes and cancels all previous discussions, agreements, commitments and writings in respect thereof. No amendment or
addition to this Agreement shall be effective unless reduced to writing and executed by the authorized representatives of the parties. 

10.13 Arbitration. 
 (a)
Any controversy or claim between the parties to this Agreement (other than any dispute which arises out of or relates to infringement, validity and/or enforceability of the XOMA Patent Rights (Text intentionally omitted.]) arising out of or relating
to this Agreement or the breach thereof shall be finally determined by arbitration in New York, in accordance with the International Arbitration Rules of the International Centre for Dispute Resolution (“ICDR”) or other rules agreed
to by the parties involved in the dispute, by a panel of three neutral arbitrators (at least two of whom who shall have significant experience in the biotechnology industry), who shall be selected by the parties involved in the dispute using the
procedures for arbitrator selection of the ICDR. 

  
 -21- 

 (b) The parties acknowledge that this Agreement evidences a transaction involving interstate
commerce and is subject to the New York Convention on enforcement of arbitral awards. Insofar as it applies, the United States Arbitration Act shall govern the interpretation of, enforcement of, and proceedings pursuant to the arbitration clause in
this Agreement. Except insofar as the United States Arbitration Act applies to such matters, the agreement to arbitrate set forth in this Section 10.13 shall be construed, and the legal relations among the parties shall be determined in
accordance with, the substantive laws of the State of New York. 
 (c) The panel shall render its decision and award, including a statement
of reasons upon which such award is based, within thirty (30) days after the arbitration hearing. The decision of the panel shall be determined by majority vote among the arbitrators, shall be in writing and shall be binding upon the parties
involved in the dispute, final and non-appealable. Judgment upon the award rendered by the panel may be entered in any court having jurisdiction thereof. 

(d) Except as provided under the United States Arbitration Act and with respect to the infringement, validity and/or enforceability of the
XOMA Patent Rights [Text intentionally omitted.], no action at law or in equity based upon any dispute that is subject to arbitration under this Section 10.13 shall be instituted. 

(e) The arbitral panel shall have the authority to award, in its discretion, part or all the expenses of any arbitration pursuant to this
Section 1 0.13, including fees and expenses of the prevailing party’s attorneys, fees and expenses of the arbitrators, and fees and expenses of any witness or the cost of any proof produced at the request of the arbitrators, to the
prevailing party. 
 10.14 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 

  
 -22- 

 IN WITNESS WHEREOF, XOMA and AFFIMED have executed this Agreement in duplicate originals by duly
authorized officers. 
  

									
	AFFIMED THERAPEUTICS AG	 		 	XOMA IRELAND LIMITED
					
	By:	 	  
	 		 	By:	 	  

		 	 Name:
 Title:
	 		 		 	 Alan Kane, Director
 duly authorized for and on
behalf of XOMA Ireland Limited in the presence of:

					
		 		 		 		 	  

  
 -23- 

 SCHEDULE 1.34 

XOMA Patent Rights 
  

			
	Title:	 	Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use
		
	Inventors:	 	Robinson, Liu, Horwitz, Wall, Better

  

	1)	Based on PCT/US86/02269, which is a continuation-in-part of U.S. Serial No. 06/793,980 filed November 1, 1985 (abandoned). 

 

					
	 COUNTRY
	 	 SERIAL NO.
	 	 PATENT NO.

			
	*United States	 	06/793,980	 	
	Australia	 	65981/86	 	Issued 606,320
	Canada	 	521,909	 	Abandoned
	Denmark	 	3385/87	 	Pending
	Taiwan	 	75105650	 	Issued 51922
	*United States	 	U.S. National Phase of PCT/US86/02269	 	

  

	2)	Based on PCT/US88/02514, which corresponds to U.S. Serial No. 07/077,528, which is a continuation-in-part of PCT/US86/02269 (abandoned), which is a continuation-in-part of U.S. Serial No. 06/793,980
(abandoned). 

  

					
	 COUNTRY
	 	 SERIAL NO.
	 	 PATENT NO.

			
	Australia	 	23244/88	 	Issued 632,462
	Austria	 	EP 88907510.7	 	Granted EP/0371998
	Belgium	 	EP 88907510.7	 	Granted EP/0371998
	Canada	 	572,398	 	Granted 1,341,235
	Denmark	 	192/90	 	Pending
	Europe	 	EP 88907510.7	 	Granted EP/0371998
	Europe	 	EP 95119798.7	 	Granted EP/0731167
	France	 	EP 88907510.7	 	Granted EP/0371998
	Germany	 	EP 88907510.7	 	Granted EP/0371998
	Italy	 	EP 88907510.7	 	Granted EP/0371998
	Japan	 	506481/88	 	Granted 2991720
	Luxembourg	 	EP 88907510.7	 	Granted EP/0371998
	Netherlands	 	EP 88907510.7	 	Granted EP/0371998
	Sweden	 	EP 88907510.7	 	Granted EP/0371998
	Switzerland/Liechtenstein	 	EP 88907510.7	 	Granted EP/0371998
	United Kingdom	 	EP 88907510.7	 	Granted EP/0371998
	Europe	 	EP 93100041.8	 	Granted EP/0550400
	Austria	 	EP 93100041.8	 	Granted EP/0550400

					
	 COUNTRY
	 	 SERIAL NO.
	 	 PATENT NO.

			
	Belgium	 	EP 93100041.8	 	Granted EP/0550400
	France	 	EP 93100041.8	 	Granted EP/0550400
	Germany	 	EP 93100041.8	 	Granted EP/0550400
	Italy	 	EP 93100041.8	 	Granted EP/0550400
	Luxembourg	 	EP 93100041.8	 	Granted EP/0550400
	Netherlands	 	EP 93100041.8	 	Granted EP/0550400
	Sweden	 	EP 93100041.8	 	Granted EP/0550400
	Switzerland/Liechtenstein	 	EP 93100041.8	 	Granted EP/0550400
	United Kingdom	 	EP 93100041.8	 	Granted EP/0550400
	*United States	 	07/077,528	 	

  

	3)	Based on U.S. Serial No. 07/501,092 filed March 29, 1990, which is a continuation-in-part of U.S. Serial No. 07/077,528 (Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use; Robinson,
Liu, Horwitz, Wall, Better) and of U.S. Serial No. 07/142,039 (Novel Plasmid Vector with Pectate Lyase Signal Sequence; Lei, Wilcox). 

  

					
	 COUNTRY
	 	 SERIAL NO.
	 	 PATENT NO.

			
	*United States	 	07/501,092	 	
	*United States	 	07/987,555	 	
	*United States	 	07/870,404	 	
	*United States	 	08/020,671	 	
	United States	 	08/235,225	 	5,618,920
	United States	 	08/299,085	 	5,595,898
	United States	 	08/472,691	 	6,204,023
	United States	 	08/467,140	 	5,698,435
	United States	 	08/450,731	 	5,693,493
	United States	 	08/466,203	 	5,698,417

  

			
	Title:	  	AraB Promoters and Method of Producing Polypeptides, Including Cecropins, by Microbiological Techniques
		
	Inventors:	  	Lai, Lee, Lin, Ray, Wilcox

 Based on PCT/US86/00131, which is a continuation-in-part of U.S. Serial No. 06/695,309 filed January 28, 1985
(abandoned). 
  

					
	 COUNTRY
	 	 SERIAL NO.
	 	 PATENT NO.

			
	 Europe
	 	EP 86900983.7	 	Granted EP/0211047
	 Austria
	 	EP 86900983.7	 	Granted EP /0211047
	 Belgium
	 	EP 86900983.7	 	Granted EP/0211047
	 France
	 	EP 86900983.7	 	Granted EP/0211047

  
 -2- 

					
	 COUNTRY
	 	 SERIAL NO.
	 	 PATENT NO.

			
	 Germany
	 	EP 86900983.7	 	Granted P3689598.9-08
	 Italy
	 	BP 86900983.7	 	Granted EP/0211047
	 Luxembourg
	 	EP 86900983.7	 	Granted EP/0211047
	 Netherlands
	 	EP 86900983.7	 	Granted EP/0211047
	 Sweden
	 	EP 86900983.7	 	Granted EP/0211047
	 Switzerland/Liechtenstein
	 	EP 86900983.7	 	Granted EP/0211047
	 United Kingdom
	 	EP 86900983.7	 	Granted EP/0211047
	 Finland
	 	863891	 	Granted 94774
	 Japan
	 	500818/86	 	Granted 2095930
	 Japan
	 	094753/94	 	Granted 2121896
	 Norway
	 	863806	 	Granted 175870
	 *United States
	 	06/695,309	 	
	 *United States
	 	06/797,472	 	
	 United States
	 	07/474,304	 	Granted 5,028,530

  

			
	Title:	  	Novel Plasmid Vector with Pectate Lyase Signal Sequence
		
	Inventors:	  	Lei, Wilcox

 Based on U.S. Application No. 07/142,039 filed January 11, 1988 and PCT/US89/00077 

 

					
	 COUNTRY
	 	 SERIAL NO.
	 	 PATENT NO.

			
	Australia	 	29377/89	 	Granted 627,443
	Canada	 	587,885	 	Granted 1,338,807
	Europe	 	EP 89901763.6	 	Granted EP/0396612
	Austria	 	EP 89901763.6	 	Granted EP/0396612
	Belgium	 	EP 89901763.6	 	Granted EP/0396612
	France	 	EP 89901763.6	 	Granted EP/0396612
	Germany	 	EP 89901783.6	 	Granted EP/0396612
	Italy	 	EP 89901763.6	 	Granted EP/0396612
	Luxembourg	 	EP 89901763.6	 	Granted EP/0396612
	Netherlands	 	EP 89901763.6	 	Granted EP/0396612
	Sweden	 	EP 89901763.6	 	Granted EP/0396612
	Switzerland/Liechtenstein	 	EP 89901763.6	 	Granted EP/0396612
	United Kingdom	 	EP 69901763.6	 	Granted EP/0396612
	Japan	 	501661189	 	Granted 2,980,626
	*United States	 	07/142,039	 	

  

	*	Cases abandoned in favor of a continuing application. 

  
 -3- 

 SCHEDULE 2.2 

Transfer of XOMA Materials 
  

	1.	Plasmid DNA 

  

	2.	Plasmid Maps 

  

	3.	Expression Strain 

  

	4.	Lab-Scale Production 

  

	5.	Fermentation Production 

 SCHEDULE 2.4 

Form of Notice 
 XOMA owns a number
of patents covering various aspects of bacterial antibody expression and phage display. 
 XOMA has licensed these patents on a non-exclusive basis to
AFFIMED. 
 Under the license agreement with XOMA: 
  

	•	 	AFFIMED cannot provide evolution or phage display services or transfer related Immunoglobulin information to you without first showing you a redacted copy of its license from XOMA and this notice. 

 

	•	 	If you and AFFIMED enter into a written agreement by which you become a “AFFIMED Collaborator,” then you will be permitted to use AFFIMED evolution or phage display services and related Immunoglobulin and
information to research, develop and commercialize antibody Immunoglobulin. 

  

	•	 	Collaborators do not, however, have either the right to (a) produce commercial quantities of such antibodies using XOMA’s patented technology or (b) commercialize any results of research conducted by
AFFIMED. Rather, AFFIMED has the right to make Research quantities of antibodies using the XOMA patent rights. AFFIMED has the right to obtain licenses from XOMA on pre-negotiated terms, but subject to certain conditions. 

 

	•	 	Therefore, if you and AFFIMED enter into a written agreement, that agreement must contain certain provisions specified in the license agreement with XOMA, including: 

 

	 	•	 	Terms pursuant to which you, as the recipient of any transferred materials, would agree to abide by each of the limitations, restrictions and other obligations provided for by the license agreement with XOMA, including,
without limitation, the restrictions on use of such transferred materials for purposes other than Research. 

  

	 	•	 	A covenant not to use transferred materials for any purpose other than for Research purposes otherwise authorized by the license agreement with XOMA. 

 

	 	•	 	A provision that the “first sale” doctrine does not apply to any disposition of transferred materials. 

	 	•	 	An agreement by you to further dispose of transferred materials only to a third party who otherwise meets the definition of a “AFFIMED Collaborator” set forth in the license agreement with XOMA and who
executes a written agreement in which it undertakes all of the obligations applied to the transferring party. 

  
 -2- 

 SCHEDULE 7.4 

For Immediate release: 
 XOMA and
Affimed Sign Antibody Cross-License and 
 Collaboration Agreement 

Berkeley, CA and Heidelberg, Germany – October 2, 2006 – XOMA Ltd. (Nasdaq: XOMA) and Affimed Therapeutics AG announced today that they
have signed a cross-license and collaboration agreement for antibody-related technologies. Financial terms were not disclosed. 
 The agreement
provides XOMA with a license under Affimed’s antibody library patents for antibody discovery purposes, as well as for the development and commercialization of antibodies. In addition, Affimed has agreed to build two customized patient-derived
human antibody phage display libraries according to XOMA specifications. 
 The agreement provides Affimed with a license to use XOMA’s Bacterial Cell
Expression (BCE) technology for research purposes, with an option to acquire a BCE license for production and commercialization of antibodies, in particular for Affimed’s proprietary TandAb and Flexibody technologies. XOMA also has agreed to
provide Affimed with cell line development and process development services specific to a TandAb therapeutic product candidate that Affimed is currently developing. 

“Affimed’s custom libraries represent a powerful addition to XOMA’s existing collection of the seven leading commercial human antibody phage
display libraries. The advantage of patient-derived libraries is their potential to contain unique antibody candidates for the therapeutic area of interest,” said Jack Castello, chairman of the board, president and chief executive officer of
XOMA. “This collaboration extends XOMA’s leadership in therapeutic antibodies, providing a single point of access to an even broader fully-integrated antibody discovery and development platform.” 

“We are delighted to enter into this broad cross-license and collaboration agreement with XOMA” said Rolf H. Günther MD PhD, chief executive
officer of Affimed. “The access to XOMA’s state-of-the-art BCE technology represents another very important milestone for Affimed and provides new opportunities for the development of Affimed’s promising recombinant antibody products.
In addition to having the rights to use this technology in our development work, we are particularly pleased to have the benefit of XOMA’s expertise in the development of cell lines and production systems for our TandAb therapeutic
candidate.” 
 About Affimed Therapeutics AG 

Affimed is a private biopharmaceutical company based in Heidelberg, Germany and specializing in the development of recombinant antibodies – the fastest
growing segment of the pharmaceutical industry. Affimed was founded in May of 2000 by Professor Melvyn Little as a spin-off of his group »Recombinant Antibodies« at the German Cancer Research Centre in Heidelberg. The strength of
Affimed’s discovery platform 

 
lies in three large distinct antibody libraries that are the source of antibody leads which can be produced in a variety of formats from scFv, diabodies, full length antibodies to proprietary
tetravalent formats such as Affimed’s TandAb or Flexibody. Affimed’s existing pipeline comprises several very novel antibody formats targeting some potentially very high value cancer targets. Two cancer products are in advanced
pre-clinical development. To learn more about Affimed, please visit www.affimed.com 
 About XOMA and its Bacterial Cell Expression Technology

 XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune
diseases. XOMA has royalty interests in RAPTIVA® (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis, and LUCENTISTM (ranibizumab injection), a monoclonal antibody product marketed worldwide (by Genentech and Novartis AG) to treat neovascular (wet) age-related macular degeneration. 

The company has built a premier antibody discovery and development platform that includes access to seven of the leading commercially available antibody phage
display libraries and XOMA’s proprietary Human EngineeringTM and BCE technologies. BCE is an enabling technology used to discover and screen, as well as develop and manufacture, recombinant proteins and antibodies for commercial purposes.
BCE is also a key technology used in multiple systems for high throughput screening of antibody domains. XOMA scientists were the first to demonstrate the secretion of antibody domains directly from the bacterial cells as fully functional, properly
folded molecules. More than 45 companies have signed BCE licenses. 
 XOMA’s development collaborators include Lexicon Genetics Inc., Novartis and
Schering-Plough Corporation. With a fully integrated product development infrastructure, XOMA’s product development capabilities extend from preclinical sciences to product launch. The company’s pipeline also includes proprietary programs
in preclinical and clinical development. In addition, XOMA leverages its recombinant protein and antibody production infrastructure through process development and manufacturing contracts with public and private sector organizations. For more
information about XOMA’s product pipeline and antibody product development capabilities and technologies, please visit XOMA’s website at http://www.xoma.com/. 

Certain statements contained herein concerning product development, customized patient-derived libraries, or that otherwise relate to future periods are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could
differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of discovery
research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or
other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties 

 
regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships;
the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA’s financing needs
and opportunities and risks associated with XOMA’s status as a Bermuda company, are described in more detail in XOMA’s most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering
XOMA’s prospects. 
  

			
	Further Information:	 	
	 FOR XOMA Ltd.
 Paul Goodson

Sr. Director, Investor Relations
 goodson@xoma.com

(510) 204-7270
	 	 FOR AFFIMED THERAPEUTICS AG:
 Dr. Douglas
Pretsell
 Account Director, Munich Bureau Chief
 Northbank
Communications
 t: +49 (0)89 57 00 18 06
 e:
d.pretsell@northbankcommunications.com

 IN WITNESS WHEREOF, XOMA and AFFIMED have executed this Agreement in duplicate originals by duly
authorized officers. 
  

											
	AFFIMED THERAPEUTICS AG	 		 	XOMA IRELAND LIMITED
					
	By:	 	 /s/ Melvyn Little
	 		 	By:	 	 /s/ Alan Kane

		 	Name:	 	Melvyn Little, Ph.D	 		 	Alan Kane, Director
		 	Title:	 	Chief Scientific Officer	 		 		 	duly authorized for and on behalf of XOMA Ireland Limited in the presence of:
						
		 		 		 		 		 	 /s/

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]